Details of the Drug

General Information of Drug (ID: DMIYDT4)

Drug Name
Cabozantinib
Synonyms Cabometyx; Cometriq
Indication
Disease Entry ICD 11 Status REF
Medullary thyroid gland carcinoma N.A. Approved [1]
Thyroid cancer 2D10 Approved [2]
Ovarian cancer 2C73 Phase 2 [2]
Affected Organisms
Humans and other mammals
ATC Code
L01EX07: Cabozantinib
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 501.5
Logarithm of the Partition Coefficient (xlogp) 5.4
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-5 h []
Half-life
The concentration or amount of drug in body reduced by one-half in 55 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 and CYP2C9 []
Vd
The volume of distribution (Vd) of drug is 349 L []
Chemical Identifiers
Formula
C28H24FN3O5
IUPAC Name
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
InChI
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
InChIKey
ONIQOQHATWINJY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
25102847
ChEBI ID
CHEBI:72317
CAS Number
849217-68-1
UNII
1C39JW444G
DrugBank ID
DB08875
TTD ID
D0IQ6P
INTEDE ID
DR0254
ACDINA ID
D00087
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [4]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [7]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Post-Translational Modifications [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Medullary thyroid gland carcinoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
Proto-oncogene c-Met (MET) DTT MET 1.08E-03 -0.24 -0.4
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 2.7816 9.8034 -1.0192 22.3557
NOS-1 [Human HNSCC] GDSC1 -1.1582 9.8189 -4.5954 47.6931
ES7 GDSC1 -0.2173 4.96 -1.427 37.8826
SK-PN-DW GDSC1 0.1366 6.5734 -1.801 37.055
H-EMC-SS GDSC1 0.1463 4.5855 -0.8896 33.5204
ES5 GDSC1 1.3026 4.2288 0.443 19.3037
CHSA0108 GDSC1 1.5539 5.0744 0.2817 19.2946
EW-7 GDSC1 1.5977 3.8779 0.8978 14.5671
HuO9 GDSC1 1.6528 5.0364 0.3926 18.0682
EW-18 GDSC1 1.8266 3.5793 1.2619 10.7594
ES1 GDSC1 1.829 3.259 1.4148 9.5834
ES8 GDSC1 1.8886 3.9423 1.1462 11.3787
EW-1 GDSC1 1.9021 4.1349 1.0649 11.9491
SK-N-MC CTRP2 2.0503 3.0987 2.0501 26.6099
MHH-ES-1 GDSC1; CTRP2 2.1506 3.2973 1.705 4.1912
EW-13 GDSC1 2.178 4.5044 1.1301 10.3262
TC-71 GDSC1 2.2022 3.6789 1.5625 6.84
CADO-ES1 GDSC1 2.27 3.5186 1.7016 5.4827
EW-11 GDSC1 2.2703 4.4151 1.2543 9.0022
SK-ES-1 GDSC1; CTRP2 2.3896 3.3324 2.3895 24.3492
ES4 GDSC1 2.5018 4.665 1.3208 7.6501
A-673 GDSC1; CTRP2 2.5051 4.3959 2.4774 23.6724
ES6 GDSC1 2.5119 5.5043 0.9099 10.8115
EW-16 GDSC1 2.5548 4.7566 1.3172 7.4985
EW-3 GDSC1 2.9357 5.8554 1.0629 8.2572
SaOS-2 GDSC1; CTRP2 2.9826 3.9311 2.9819 20.4005
CHSA8926 GDSC1 3.3165 9.0722 -0.239 16.188
CAL-78 GDSC1 3.3171 8.759 -0.084 15.2126
G-292 clone A141B1 GDSC1; CTRP2 3.5692 8.349 2.4916 20.4743
TC71 CTRP2 3.7522 6.1049 3.5261 16.0639
HuO-3N1 GDSC1 3.7999 7.4586 0.8844 7.2301
EW-24 GDSC1 3.8806 5.5998 1.7599 1.303
SJSA-1 GDSC1; CTRP2 4.1839 6.1928 2.2954 1.939
HOS GDSC1; CTRP2 4.4159 6.3748 4.167 11.736
CHSA0011 GDSC1 4.5211 10.9215 -0.2844 13.0716
CAL-72 GDSC1 4.6512 6.0554 1.9044 0.2173
Hs 888.T CTRP2 4.6677 9.7773 2.9352 15.9498
MG-63 GDSC1; CTRP2 4.6879 7.1389 4.1687 10.9662
NY GDSC1 4.7353 7.0079 1.5886 1.2344
SW1353 CTRP2 4.7501 11.802 2.0267 19.2682
U2OS GDSC1; CTRP2 6.2552 23.4247 -5.1319 23.5476
Hs 822.T CTRP2 6.4592 8.4869 5.1492 3.0339
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 208 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 0.0163 4.406 -0.1703 40.6485
MEC1 CTRP2 2.2021 5.7018 1.9395 26.4992
JM1 GDSC1; CTRP2 3.2101 5.2179 3.1314 19.1502
EoL-1 GDSC1; CTRP2 -10.8068 -9.1998 -10.8068 99.6219
MOLM-13 GDSC1; CTRP2 -6.9647 -5.011 -6.9647 86.0751
MV4-11 GDSC1; CTRP2 -6.3131 6.3122 -7.5158 74.1176
NKM-1 GDSC1 -5.2453 -2.02 -5.2618 84.7255
MOLM-16 CTRP2 -5.2144 1.3611 -5.3503 70.4584
ALL-PO GDSC1 -3.8228 1.7998 -4.2438 67.2022
Mono-Mac-6 GDSC1; CTRP2 -3.6664 9.1655 -5.5441 58.2598
GDM-1 GDSC1 -3.4218 1.5328 -3.7453 65.3777
Kasumi-1 CTRP2 -3.2934 1.8381 -3.3776 61.1784
MY-M12 GDSC1 -1.6738 2.2861 -2.0229 50.3009
SU-DHL-16 GDSC1 -1.378 2.1413 -1.6625 47.1846
SEM CTRP2 -0.8523 6.9188 -1.7379 46.817
BV-173 GDSC1 -0.5369 1.8609 -0.681 36.9679
LAMA-84 GDSC1; CTRP2 -0.5046 1.7383 -0.6215 25.7962
Mono-Mac-1 CTRP2 -0.4912 15.5367 -4.8452 46.9459
MEG-01 GDSC1 -0.4481 1.5455 -0.527 35.5199
ALL-SIL GDSC1; CTRP2 -0.2387 2.3882 -0.2511 41.895
OCI-AML-5 GDSC1; CTRP2 -0.0739 2.9364 -0.105 40.8512
Ku812 GDSC1; CTRP2 -0.0036 2.2638 -0.1945 21.7227
MOLM-6 CTRP2 0.0405 3.272 -0.0083 40.1413
JURL-MK1 GDSC1; CTRP2 0.1094 1.6975 0.109 39.5412
EM-2 GDSC1; CTRP2 0.2864 2.6835 0.2753 38.3963
BE-13 GDSC1 0.3996 3.3359 -0.1085 27.7524
K-562 GDSC1; CTRP2 0.4941 2.8135 0.4832 37.0126
CML-T1 CTRP2 0.6825 3.1982 0.6616 35.79
Karpas-45 GDSC1 0.7903 3.2493 0.3413 22.6144
KCL-22 GDSC1; CTRP2 0.8267 2.3438 0.6904 14.1402
Pfeiffer CTRP2 1.1068 3.6415 1.0753 32.9993
CTV-1 GDSC1 1.2208 2.7047 1.0071 15.6322
P30/OHK GDSC1 1.2868 3.4893 0.7619 17.0601
A4/Fukuda GDSC1; CTRP2 1.2941 5.7364 0.941 32.7907
SIG-M5 GDSC1; CTRP2 1.3183 3.4706 1.3027 31.538
KG-1 GDSC1 1.3953 3.9028 0.686 17.0921
697 GDSC1; CTRP2 1.4238 3.6503 1.4028 30.8529
MOLT-16 GDSC1; CTRP2 1.4308 4.0911 1.3784 30.9115
NALM-6 GDSC1; CTRP2 1.45 2.7054 1.2538 8.9439
EB2 GDSC1 1.4966 4.9347 0.2954 19.4559
EB1 CTRP2 1.5378 5.9041 1.1638 31.2609
RS4;11 GDSC1; CTRP2 1.5467 4.1488 1.0197 14.9668
Ramos.2G6.4C10 GDSC1 1.5861 4.3819 0.6469 16.5007
HAL-01 GDSC1 1.6172 3.9035 0.9047 14.4256
P32/ISH GDSC1 1.6216 3.1344 1.2611 11.7261
KYO-1 CTRP2 1.646 2.6773 1.646 29.3027
SU-DHL-5 GDSC1 1.6547 3.5445 1.1095 12.7045
SUP-B15 GDSC1; CTRP2 1.6648 4.4438 1.5879 29.4356
Reh GDSC1 1.7157 2.6995 1.5407 9.2057
MLMA GDSC1 1.7216 6.0343 -0.0352 20.7221
Farage GDSC1 1.7269 3.3876 1.2539 11.2765
Loucy GDSC1 1.7549 2.6203 1.6128 8.483
Peer CTRP2 1.7616 4.2081 1.715 28.6888
Daudi GDSC1; CTRP2 1.7973 4.2408 1.7495 28.4554
WSU-NHL GDSC1 1.8805 9.5118 -1.6254 28.4572
SUP-M2 GDSC1; CTRP2 1.9026 2.4306 1.9026 27.5933
GA-10 CTRP2 2.0311 5.3522 1.8323 27.414
NOMO-1 GDSC1 2.05 6.201 0.173 17.9609
ST486 GDSC1; CTRP2 2.0528 4.0479 2.0307 26.6666
MOLT-4 GDSC1 2.0552 3.7134 1.4129 8.6051
SR GDSC1 2.0982 2.8292 1.881 4.7995
MHH-PREB-1 GDSC1 2.1053 5.1151 0.7624 13.4481
ATN-1 GDSC1 2.1123 3.2038 1.7152 6.0131
CCRF-CEM GDSC1 2.1358 3.8115 1.4375 8.0844
MOLT-3 CTRP2 2.1375 2.9939 2.1375 26.0281
Mino CTRP2 2.1881 3.5942 2.185 25.7014
KMS-11 GDSC1 2.207 4.3512 1.2317 9.4193
SU-DHL-6 GDSC1; CTRP2 2.2226 4.3339 2.1873 25.5801
RPMI-8402 GDSC1; CTRP2 2.2284 4.0862 2.2101 25.4839
AML-193 CTRP2 2.2405 3.4055 2.2397 25.3447
OPM-2 GDSC1; CTRP2 2.2665 3.6681 2.2631 25.1803
VAL GDSC1 2.269 4.4171 1.2521 9.0241
KE-37 GDSC1; CTRP2 2.2726 2.9531 2.2726 25.1285
LP-1 GDSC1; CTRP2 2.275 3.6655 2.2717 25.1233
WIL2 NS GDSC1 2.2804 4.9974 0.9719 11.1686
RPMI-6666 GDSC1; CTRP2 2.2905 6.8956 1.6872 27.0979
QIMR-WIL GDSC1 2.2974 3.6789 1.6452 5.823
JSC-1 GDSC1 2.3685 3.7425 1.6732 5.341
PL-21 GDSC1 2.3731 4.8969 1.0999 9.8328
BC-1 GDSC1 2.3883 3.8945 1.6136 5.7408
SCC-3 GDSC1 2.4004 3.2862 1.9274 3.2245
TK [Human B-cell lymphoma] GDSC1 2.4168 4.8159 1.1764 9.0784
TUR GDSC1 2.4387 3.924 1.6399 5.3562
U-698-M GDSC1 2.448 4.773 1.2233 8.6007
Ki-JK CTRP2 2.4885 3.3502 2.4884 23.6905
ML-2 GDSC1 2.5 3.8867 1.7072 4.6202
SU-DHL-4 GDSC1; CTRP2 2.5021 5.0807 2.3926 23.972
RPMI-8866 GDSC1 2.5248 4.3587 1.4917 6.2301
MOLT-13 GDSC1 2.5333 4.052 1.651 4.9516
KE-97 CTRP2 2.5427 3.8537 1.5349 2.0206
KMS-34 CTRP2 2.5511 3.1468 2.5511 23.2731
SUP-T1 GDSC1 2.552 4.5859 1.4 6.8588
GR-ST GDSC1 2.5586 4.7644 1.3163 7.4924
Sc-1 GDSC1 2.5609 8.9472 -0.7704 21.8285
H9 GDSC1 2.5654 4.1743 1.615 5.1294
CA46 GDSC1; CTRP2 2.5677 5.9688 2.2705 24.1938
Ri-1 CTRP2 2.5727 4.8042 2.5083 23.3467
JVM-3 GDSC1; CTRP2 2.5949 4.9812 1.2369 5.652
VL51 GDSC1 2.6023 5.4642 1.0022 9.7902
TALL-1 [Human adult T-ALL] CTRP2 2.6364 4.8721 2.5673 22.9386
KMS-21-BM CTRP2 2.64 4.4231 2.616 22.7611
YT GDSC1 2.6427 7.4091 0.0643 16.4756
DEL GDSC1; CTRP2 2.6569 3.0202 2.6569 22.5679
NB4 GDSC1 2.6958 3.7855 1.9009 2.5308
P31/FUJ GDSC1; CTRP2 2.7026 3.0911 2.7026 22.2634
MM1.S CTRP2 2.7057 4.2175 2.695 22.2785
BC-3 GDSC1 2.7494 4.6872 1.4999 5.4546
HC-1 GDSC1 2.7528 6.5438 0.583 12.4469
SU-DHL-1 GDSC1; CTRP2 2.7766 3.0974 2.7766 21.7704
BL-70 CTRP2 2.8095 3.7454 2.8091 21.5525
RCH-ACV CTRP2 2.8213 4.4322 2.8034 21.5327
P12-Ichikawa GDSC1 2.8217 4.4719 1.6566 4.0416
A3/Kawakami GDSC1; CTRP2 2.8282 6.729 2.3262 23.2014
HEL GDSC1; CTRP2 2.8346 3.9877 1.8963 1.5655
MJ CTRP2 2.8368 16.9047 -2.2458 35.3079
PL21 CTRP2 2.841 4.1157 2.8363 21.3572
KY821 GDSC1 2.8448 4.4773 1.67 3.8766
ARH-77 GDSC1 2.8602 5.2937 1.2833 6.7947
Hs 445 GDSC1 2.8819 4.7179 1.5795 4.4619
KOPN-8 GDSC1 2.8926 6.2657 0.8285 10.1659
MOLP-8 GDSC1; CTRP2 2.9093 5.3333 2.7876 21.3027
OCI-Ly19 GDSC1; CTRP2 2.9255 6.2171 2.5919 21.9479
JeKo-1 CTRP2 2.9393 6.6012 2.4889 22.2793
Namalwa GDSC1; CTRP2 2.9636 6.0998 2.667 21.5616
HH [Human lymphoma] GDSC1; CTRP2 2.973 6.4344 2.5784 21.8532
KMOE-2 GDSC1 3.0143 4.9718 1.5478 4.3477
Hs 611.T CTRP2 3.0242 6.0208 2.7548 21.061
SUP-T11 CTRP2 3.0696 4.8154 3.0329 19.9422
MOTN-1 CTRP2 3.1436 6.4742 2.7516 20.7119
Karpas-299 GDSC1 3.1444 4.7166 1.7502 2.5661
KO52 CTRP2 3.1674 5.8549 2.9543 19.9072
L-540 GDSC1; CTRP2 3.1922 4.8917 3.1545 19.1289
CESS GDSC1 3.2265 5.8107 1.2893 5.7273
SU-DHL-8 GDSC1; CTRP2 3.3318 6.911 2.8091 19.9463
BALL-1 GDSC1 3.3476 6.7868 0.9028 8.2676
KHM-1B CTRP2 3.3669 5.1799 1.4169 1.4116
OCI-AML-3 GDSC1; CTRP2 3.3736 5.4143 3.2743 18.1328
KMS-18 CTRP2 3.3865 5.3707 3.296 18.016
LC4-1 GDSC1 3.4027 11.3581 -1.3051 21.7252
Toledo CTRP2 3.4043 6.3769 3.0659 18.7852
JVM-2 GDSC1 3.4081 6.2459 1.2025 5.9048
U-937 CTRP2 3.4098 8.1455 2.4115 21.2131
RPMI-8226 GDSC1 3.4191 6.3932 1.1399 6.3356
NU-DUL-1 GDSC1; CTRP2 3.4846 5.4587 3.3861 17.3908
SUP-HD1 GDSC1; CTRP2 3.4906 6.6442 3.0732 18.5032
CMK CTRP2 3.5216 5.6296 3.3924 17.2521
RC-K8 GDSC1 3.5701 5.029 1.8446 1.2369
SU-DHL-10 GDSC1; CTRP2 3.5743 5.2304 3.5195 16.6421
MN-60 GDSC1 3.5897 5.8033 1.5197 3.2439
L-363 GDSC1; CTRP2 3.6341 5.4885 3.5422 16.3722
KMS-12-BM GDSC1; CTRP2 3.6392 6.0689 3.4128 16.8166
KMS-28BM CTRP2 3.6491 5.1853 3.605 16.1069
TF-1 CTRP2 3.7421 7.5064 3.0229 17.9768
SK-MM-2 GDSC1; CTRP2 3.7835 6.4341 1.9258 4.3713
EHEB CTRP2 3.8116 7.4591 3.1153 17.4311
HuNS1 CTRP2 3.8237 13.9124 0.1349 27.6549
OCI-AML-2 GDSC1 3.8667 6.8238 1.2203 4.7265
Kasumi-2 CTRP2 3.8738 5.48 3.8024 14.7044
Jiyoye GDSC1 3.8885 6.3549 1.4432 3.1878
PF-382 GDSC1; CTRP2 3.9033 6.0665 3.7017 19.2239
WSU-DLCL2 GDSC1; CTRP2 3.9078 5.1772 3.8799 14.3281
Raji GDSC1 3.9105 6.088 1.571 2.3436
M-07e CTRP2 3.9353 6.0286 3.7469 14.7096
Granta-519 GDSC1; CTRP2 3.9526 6.6161 3.5833 15.2592
THP-1 GDSC1; CTRP2 3.958 6.0066 3.7777 14.5296
Karpas-620 GDSC1; CTRP2 3.9603 6.8333 3.5145 15.4953
HD-MY-Z CTRP2 3.9708 6.1651 3.7473 14.6004
KMS-20 CTRP2 3.9753 5.6351 3.8834 14.1
HEL 92.1.7 CTRP2 4.0141 7.4952 3.3144 16.1095
NCI-H929 CTRP2 4.04 5.6727 3.9461 18.6448
DB GDSC1; CTRP2 4.055 7.0715 3.5265 15.1816
F-36P CTRP2 4.0782 6.3397 3.8113 14.0458
ME1 GDSC1 4.1823 5.3954 1.9634 0.2482
MC116 GDSC1; CTRP2 4.2359 5.5517 4.1801 12.2387
HPB-ALL CTRP2 4.3424 5.9569 4.2101 11.7993
REC-1 CTRP2 4.3456 7.0574 3.8411 13.1684
L-1236 GDSC1 4.4315 9.3099 0.4192 8.8973
EJM GDSC1; CTRP2 4.4387 7.9579 3.5571 14.0306
MHH-CALL-3 CTRP2 4.4414 20.7972 -2.7071 32.4225
JJN-3 GDSC1; CTRP2 4.4549 6.3726 4.2102 11.4615
HT GDSC1; CTRP2 4.4581 5.1405 4.4544 10.5806
Jurkat CTRP2 4.464 5.8919 1.6118 0.1462
DND-41 GDSC1; CTRP2 4.5416 6.4919 4.2636 11.0101
HL-60 GDSC1; CTRP2 4.5431 6.4926 4.2648 11.0012
HuT 78 CTRP2 4.5807 7.1682 4.0442 11.7401
Karpas-422 GDSC1; CTRP2 4.5821 5.8553 4.4959 10.0396
OCI-Ly3 CTRP2 4.6027 8.2354 3.5979 13.4497
KM-H2 GDSC1; CTRP2 4.6263 9.2476 0.5682 5.4053
SET-2 CTRP2 4.732 5.8561 4.6588 8.9958
MHH-CALL-4 CTRP2 4.8126 5.8813 4.7408 8.4543
AMO1 GDSC1; CTRP2 4.8965 6.441 4.6647 8.4829
RL GDSC1; CTRP2 4.9762 8.2935 3.9405 11.1457
NU-DHL-1 CTRP2 4.9802 7.0629 4.5051 8.8689
L-428 GDSC1; CTRP2 5.0332 7.0935 4.5466 8.5657
KMS-26 CTRP2 5.1942 6.8457 4.8199 9.631
OCI-M1 GDSC1; CTRP2 5.2313 8.3136 4.177 9.5734
Ci-1 CTRP2 5.2425 7.2226 4.7021 7.4084
U266B1 GDSC1; CTRP2 5.3603 9.4715 3.732 11.1204
ROS-50 GDSC1 5.3732 12.1845 -0.329 11.3269
P3HR-1 CTRP2 5.3779 8.1566 4.3919 8.3492
DG-75 GDSC1 5.3848 7.1351 1.7951 0.2199
MOLP-2 CTRP2 5.481 6.8731 5.1009 5.2068
KMM-1 CTRP2 5.5318 9.8381 3.7051 10.8613
CTB-1 GDSC1 5.6692 7.7318 1.6918 0.3391
BL-41 GDSC1; CTRP2 5.8419 16.1826 0.8056 21.0944
HDLM-2 GDSC1; CTRP2 6.1164 8.7002 4.776 6.6699
OCI-Ly10 CTRP2 6.4077 13.1545 2.7874 12.8686
KMS-27 CTRP2 7.7561 9.8811 5.295 1.3818
⏷ Show the Full List of 208 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 2.9571 5.8165 1.5906 7.9111
TE15 CTRP2 3.7338 9.6154 2.0963 21.5153
OE33 GDSC1; CTRP2 1.4694 8.1762 0.342 33.924
KYSE-180 GDSC1; CTRP2 1.7462 8.4835 -1.2296 20.7888
TE-15 GDSC1 2.2999 5.3102 0.832 12.1732
T.T GDSC1 2.6838 4.3512 1.6168 4.7462
TE-8 GDSC1 2.8285 6.5545 0.6365 11.8022
KYSE-270 GDSC1 2.9299 4.9623 1.4947 4.9747
TE-11 GDSC1; CTRP2 3.4267 5.499 3.3159 17.8195
TE-4 GDSC1; CTRP2 3.4336 5.0365 2.3579 2.8284
TE-6 GDSC1; CTRP2 3.4983 6.5921 1.6396 6.4123
KYSE-140 GDSC1; CTRP2 3.5446 7.2248 0.8269 5.9091
KYSE-410 GDSC1 3.6729 5.8106 1.5636 2.794
OE21 GDSC1; CTRP2 3.8485 5.8645 3.6946 15.1636
TE-1 GDSC1; CTRP2 4.0411 6.6179 3.6784 14.6472
EC-GI-10 GDSC1; CTRP2 4.2625 7.0584 3.7525 13.7389
TE-14 CTRP2 4.4179 7.4374 3.7614 13.2812
COLO 680N GDSC1; CTRP2 4.8548 7.0688 4.3723 9.7231
KYSE-150 GDSC1; CTRP2 4.8627 7.9704 3.9794 11.2666
KYSE-70 GDSC1; CTRP2 5.075 7.4053 4.4506 8.8399
OE19 GDSC1; CTRP2 5.1076 6.8129 3.4517 1.4148
TE-9 GDSC1; CTRP2 5.2616 7.4372 4.6223 9.8656
KYSE-510 GDSC1; CTRP2 5.7665 8.9492 4.3544 7.6586
KYSE-30 CTRP2 5.768 7.7257 4.9636 5.1061
KYSE-450 GDSC1; CTRP2 5.7742 8.8952 4.388 7.5018
TE-10 GDSC1; CTRP2 5.834 9.2605 4.2578 10.17
TE-5 GDSC1; CTRP2 6.1238 8.7159 4.7742 5.1877
KYSE-520 GDSC1; CTRP2 6.98 13.0195 3.3026 9.7849
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 5.3329 7.0909 4.8529 6.5753
MZ-PC-1 GDSC1 0.7325 4.4444 -0.2273 26.6557
KP-4 GDSC1; CTRP2 2.1916 6.8715 1.5879 27.7457
PL4 GDSC1 2.6227 7.741 -0.1175 17.7393
HuP-T4 GDSC1; CTRP2 2.6417 5.6617 2.428 23.407
Panc 05.04 CTRP2 2.6696 13.9776 -0.9948 33.4176
Panc 03.27 GDSC1; CTRP2 2.7151 7.631 1.8813 25.1348
KP-3 GDSC1; CTRP2 2.7874 4.9619 1.3929 4.3601
PK-59 CTRP2 3.0069 6.6189 2.5565 21.8314
BxPC-3 GDSC1; CTRP2 3.1345 5.8497 2.9197 20.1325
HPAC GDSC1; CTRP2 3.262 10.4236 1.2538 25.7365
HPAF-II GDSC1; CTRP2 3.3135 8.0306 0.2718 9.3209
SU.86.86 GDSC1; CTRP2 3.5118 4.9188 2.4693 2.1197
MIA PaCa-2 GDSC1; CTRP2 3.7027 5.8567 3.5376 16.1739
SW1990 GDSC1; CTRP2 3.7914 6.5067 3.4455 16.2423
CFPAC-1 GDSC1; CTRP2 3.9197 6.333 3.6408 15.143
SNU-213 CTRP2 3.9272 10.263 1.9871 21.4164
PK-45H CTRP2 4.0913 10.1995 2.1774 20.2953
DAN-G GDSC1; CTRP2 4.1039 6.4738 3.7956 14.028
Panc 08.13 GDSC1; CTRP2 4.238 9.5646 2.6198 18.2387
Capan-2 GDSC1; CTRP2 4.4487 7.6959 3.6825 13.509
TCC-Pan2 CTRP2 4.4561 7.8284 3.6322 13.6883
KP-2 GDSC1; CTRP2 4.461 6.8893 4.0297 12.1248
AsPC-1 GDSC1; CTRP2 4.5652 8.096 3.6237 13.4416
Capan-1 GDSC1; CTRP2 4.6079 8.4842 3.4887 13.8747
YAPC GDSC1; CTRP2 4.766 7.1682 4.2378 10.4869
PaTu 8988s CTRP2 4.8009 6.9528 4.3642 9.8997
Panc 02.03 GDSC1; CTRP2 4.8705 10.4812 2.7852 16.0722
HuP-T3 GDSC1; CTRP2 4.902 9.7203 3.1851 14.3957
Panc 10.05 GDSC1; CTRP2 4.9864 9.3041 3.4663 13.0569
PSN1 GDSC1; CTRP2 5.0686 7.0602 4.5975 8.2717
Hs 766T GDSC1 5.0821 6.7968 1.8034 0.2922
PaTu 8988t GDSC1; CTRP2 5.2835 8.5073 4.1329 9.6343
Panc 04.03 GDSC1; CTRP2 5.5038 8.5825 4.3008 8.4434
QGP-1 GDSC1; CTRP2 5.5431 11.0471 3.114 13.2697
L3.3 CTRP2 5.5964 8.8079 4.2736 8.3552
SNU-410 CTRP2 5.662 8.6726 4.3995 7.6893
PaTu 8902 GDSC1; CTRP2 6.8447 10.9245 4.2349 6.1911
SUIT-2 GDSC1; CTRP2 7.9852 9.655 5.4887 0.3792
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 76 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 4.7986 8.2735 3.2206 8.7341
COLO 792 GDSC1; CTRP2 0.9193 7.8277 -0.1202 37.0078
VMRC-MELG GDSC1 1.3763 4.0466 0.6007 17.8095
CHL-1 GDSC1 1.7295 3.3597 1.2693 11.1484
WM35 GDSC1 1.8518 3.2169 1.4569 9.1577
CP50-MEL-B GDSC1 2.2117 4.8952 0.9643 11.4865
SH-4 GDSC1 2.2181 4.5596 1.1374 10.1153
Mel Ho GDSC1; CTRP2 2.3734 3.3693 1.8639 2.699
WM278 GDSC1 2.4059 4.2212 1.4647 6.8516
A-431 GDSC1 2.4114 5.9863 0.5869 13.6113
M14 GDSC1 2.4305 6.4722 0.3597 15.1944
Hs 839.T CTRP2 2.4357 12.7219 -0.6309 33.2824
A-388 GDSC1 2.6659 4.3637 1.5974 4.9514
G-mel GDSC1 2.7783 4.486 1.6192 4.4497
LOX-IMVI GDSC1; CTRP2 2.8858 4.1183 2.8818 21.0564
MZ-MEL-7 GDSC1 2.905 5.8375 1.049 8.4557
IST-MEL1 GDSC1 2.95 5.7739 1.1134 7.8285
WM88 CTRP2 2.9814 6.7778 2.4761 22.2003
DJM-1 GDSC1 2.9838 4.5886 1.7096 3.2235
COLO 783 GDSC1 3.0574 5.0007 1.5627 4.1266
MZ-MEL-2 GDSC1 3.1256 4.9726 1.6201 3.5381
HMV-II GDSC1 3.1711 5.2289 1.5289 4.0946
HT-144 GDSC1; CTRP2 3.2452 5.6407 3.0896 19.1854
LB2518-MEL GDSC1 3.2987 5.2752 1.5873 3.38
G-361 GDSC1; CTRP2 3.3275 5.0864 3.2755 18.2765
Malme-3M CTRP2 3.3641 6.465 2.9945 19.1664
A2058 GDSC1 3.3658 4.5269 1.9522 0.9114
Hs 895.T CTRP2 3.4167 11.8245 0.752 26.9143
MMAc-SF GDSC1 3.4174 6.1608 1.2488 5.5434
LB373-MEL-D GDSC1 3.4748 8.9183 -0.0458 14.4859
WM266-4 CTRP2 3.5169 8.3169 2.4511 20.7698
GAK GDSC1 3.5202 5.42 1.6511 2.4993
CP66-MEL GDSC1 3.5364 5.1849 1.7621 1.7674
SK-MEL-24 GDSC1; CTRP2 3.63 8.6453 2.4262 20.5566
COLO 829 GDSC1; CTRP2 3.6872 6.338 3.3861 16.7692
RPMI-7951 GDSC1; CTRP2 3.6997 6.12 3.4645 16.4457
Hs 852.T CTRP2 3.7017 7.3376 3.0468 17.9979
Hs 938.T GDSC1 3.7088 5.4702 1.7296 1.7009
451Lu GDSC1 3.7687 5.6313 1.692 1.8337
Hs 294T CTRP2 3.7762 6.0486 3.5679 15.8396
WM1799 CTRP2 3.7808 7.2198 3.1768 17.2822
COLO 679 GDSC1 3.8561 5.7346 1.6926 1.7052
A-375 GDSC1; CTRP2 3.9638 6.0416 3.7746 14.5229
HMCB CTRP2 4.0085 6.3585 3.7295 14.5531
WM115 GDSC1; CTRP2 4.1713 7.8253 3.3401 15.586
WT2-iPS GDSC1; CTRP2 4.242 6.6633 3.8793 13.3148
MeWo GDSC1; CTRP2 4.2441 8.0144 3.3331 15.4213
MDA-MB-435S CTRP2 4.2647 8.1761 3.2829 15.5653
WM793 GDSC1; CTRP2 4.5321 7.346 3.919 12.3592
WM983B CTRP2 4.5385 7.9937 3.6428 13.4334
IGR-1 GDSC1; CTRP2 4.6683 7.7 3.9058 12.0536
SK-MEL-3 GDSC1; CTRP2 4.6738 9.7 2.9781 15.7639
IGR-39 CTRP2 4.6854 7.683 3.9309 11.91
COLO 800 GDSC1; CTRP2 4.7088 8.6188 3.5257 13.4768
CJM [Human melanoma] CTRP2 4.8025 6.9805 4.3545 9.9331
WM1552C GDSC1 4.9206 6.53 1.8375 0.2721
Mel JuSo GDSC1; CTRP2 4.9471 7.6898 4.1925 10.1981
UACC-257 GDSC1; CTRP2 4.9684 9.0494 3.5723 12.6661
Hs 944.T CTRP2 4.9685 9.0312 3.5811 12.6299
SK-MEL-5 GDSC1; CTRP2 4.9699 8.8995 3.6457 12.3631
RVH-421 GDSC1; CTRP2 5.0083 8.4151 3.9142 11.1761
Hs 940.T GDSC1; CTRP2 5.1459 8.2008 4.1492 9.8882
UACC-62 GDSC1; CTRP2 5.16 8.41 4.0626 10.21
A101D GDSC1; CTRP2 5.2049 10.8935 2.889 14.9054
IPC-298 GDSC1; CTRP2 5.4488 8.1552 4.4592 7.9096
IGR-37 GDSC1; CTRP2 5.4801 11.5458 2.8103 14.6259
SK-MEL-28 GDSC1; CTRP2 5.7161 9.825 3.874 9.772
Hs 688(A).T CTRP2 5.7221 9.4468 4.0676 8.951
SK-MEL-31 CTRP2 5.7878 10.0165 3.8407 9.7645
COLO 741 CTRP2 5.8486 9.0376 4.3816 7.3763
K029AX CTRP2 6.0801 10.0877 4.0524 8.3013
SK-MEL-2 GDSC1; CTRP2 6.2814 7.9189 5.2966 2.7143
SK-MEL-30 GDSC1; CTRP2 7.0439 13.6656 3.0313 10.7634
Hs 936.T CTRP2 7.5928 10.2544 5.0469 1.9827
SK-MEL-1 GDSC1; CTRP2 7.9061 9.0541 5.6749 0.1249
EquiPSC Line K2 GDSC1 3.253 5.6004 1.4067 4.7915
⏷ Show the Full List of 76 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESO-51 GDSC1 -4.0086 -2.2468 -4.0091 78.3365
KYSE-50 GDSC1 1.6499 10.1379 -2.1379 31.2803
OACM5.1 C GDSC1 2.0268 5.6365 0.434 16.204
OACP4 C GDSC1 2.3626 3.7625 1.6584 5.4794
FLO-1 GDSC1 2.3632 5.7957 0.6423 13.3755
ESO-26 GDSC1 2.5396 5.2309 1.0686 9.4902
TE-12 GDSC1 2.7415 6.3901 0.6506 11.986
KYAE-1 GDSC1 2.7995 4.5162 1.6196 4.3858
SK-GT-4 GDSC1 2.8592 5.3102 1.2745 6.8658
KYSE-220 GDSC1 3.2681 5.6598 1.3885 4.8878
HCE-4 GDSC1 5.0801 6.8261 1.7925 0.3172
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1 3.3495 6.4717 1.0558 7.1356
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-7 GDSC1 1.734 2.8576 1.496 9.4359
IMR-5 GDSC1 1.7416 3.0386 1.4263 9.9125
NB(TU)1 GDSC1 1.8163 7.8748 -0.865 25.1992
GI-ME-N GDSC1 1.9128 5.9681 0.1686 18.5472
NH-12 GDSC1 1.9571 3.1797 1.5781 7.753
SJNB-14 GDSC1 1.9589 3.6036 1.3768 9.2929
CHP-212 GDSC1; CTRP2 2.0846 2.9754 2.0845 26.3812
CHP-134 GDSC1 2.1174 2.879 1.8764 4.7475
NB69 GDSC1 2.2314 3.8704 1.4927 7.275
SJNB-10 GDSC1 2.3733 3.6319 1.7325 4.8569
SJNB-13 GDSC1 2.4092 4.5263 1.315 8.0183
TGW GDSC1 2.4154 4.058 1.5541 6.1143
Kelly GDSC1 2.6017 3.9391 1.7589 3.8924
GOTO GDSC1 2.6853 4.2353 1.6748 4.2925
MHH-NB-11 GDSC1 2.6866 5.5456 1.0278 9.3119
SiMa GDSC1 2.7215 4.6965 1.4748 5.7338
KP-N-YS GDSC1 2.725 5.2582 1.1999 7.8568
SK-N-FI GDSC1; CTRP2 2.7798 4.2543 2.7695 21.7838
NB1 GDSC1; CTRP2 2.8115 4.2628 2.8017 21.5708
SJNB-6 GDSC1 2.8601 5.0736 1.3911 5.9663
SK-N-SH GDSC1; CTRP2 2.8647 4.7368 2.8248 21.3179
SJNB-17 GDSC1 2.8945 5.5345 1.1903 7.4068
SJNB-12 GDSC1 2.9679 6.5648 0.7374 10.6092
LA-N-6 GDSC1 3.0432 6.191 0.9768 8.5867
NH-6 CTRP2 3.4299 6.3704 3.0959 18.5993
CHP-126 GDSC1; CTRP2 3.6751 5.3808 3.605 16.0234
SK-N-MC-IXC GDSC1 3.86 4.9914 1.9855 0.338
SK-N-BE(2)-M17 GDSC1 4.3146 6.216 1.7124 1.0703
SJNB-5 GDSC1 4.5301 7.2468 1.3969 2.4531
SK-N-AS GDSC1; CTRP2 4.5738 6.5994 4.2598 10.9319
SK-N-DZ GDSC1; CTRP2 4.6454 7.5219 3.9608 11.8955
SK-N-BE(2) CTRP2 5.5244 8.9444 4.1411 9.0629
KP-N-YN GDSC1; CTRP2 5.5893 6.6547 5.3091 4.0985
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 2.2846 3.8101 2.2785 25.0685
SNU-1196 CTRP2 3.8391 6.4689 3.5097 15.8646
SNU-478 CTRP2 4.6719 8.077 3.7397 17.2982
HuH-28 CTRP2 4.6848 7.6948 3.925 16.2606
HuCC-T1 GDSC1; CTRP2 4.8208 10.1509 2.8996 15.732
SNU-869 CTRP2 4.9985 9.5867 3.3406 13.5416
SNU-308 CTRP2 6.4 12.5952 3.0604 15.7357
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 90 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFM-223 GDSC1 1.3755 3.9459 0.6464 17.4775
HCC1599 GDSC1 2.4091 3.492 1.8317 3.9482
COLO 824 GDSC1 2.4699 4.7461 1.2546 8.2794
HCC1806 GDSC1; CTRP2 2.5976 3.8322 1.8084 2.4872
Evsa-T GDSC1 2.7235 4.688 1.4804 5.6841
MDA-MB-468 GDSC1; CTRP2 2.7702 4.1183 2.7643 21.8327
OCUB-M GDSC1 2.8637 5.5213 1.1741 7.6246
DU4475 GDSC1; CTRP2 2.8653 4.4199 2.8497 21.2317
MRK-nu-1 GDSC1 2.928 4.759 1.5914 4.2474
EFM-192A GDSC1 3.046 6.6546 0.7512 10.2645
EFM-19 GDSC1 3.0785 7.2449 0.4846 12.105
HCC1187 GDSC1 3.209 5.9043 1.2326 6.1956
HCC70 GDSC1 3.3547 5.3664 1.5794 3.3144
HCC1143 CTRP2 3.4621 5.8019 3.2886 17.8051
CAL-85-1 GDSC1; CTRP2 3.6798 6.5118 3.3226 17.025
YMB-1-E GDSC1 3.797 5.9494 1.5706 2.5317
BT-20 GDSC1; CTRP2 3.8738 5.6013 3.7801 14.7823
MDA-MB-436 GDSC1 3.936 6.1343 1.5645 2.3434
BT-483 GDSC1 3.992 5.5517 1.8296 0.8441
UACC-893 GDSC1 4.0061 6.8567 1.2867 3.9982
Hs 578Bst CTRP2 4.0227 7.2819 3.4097 15.7188
HCC2157 GDSC1 4.0662 5.7517 1.7842 0.9801
MDA-MB-175-VII GDSC1 4.1158 6.7575 1.3911 3.1239
MDA-MB-415 GDSC1 4.2386 6.08 1.7321 1.0534
CAL-51 GDSC1; CTRP2 4.2418 6.798 3.83 13.5018
MDA-MB-330 GDSC1 4.5271 7.0147 1.4911 1.9388
HCC38 GDSC1; CTRP2 4.5541 8.3973 3.4751 14.0632
MDA-MB-453 GDSC1; CTRP2 4.6339 6.9215 4.2007 10.989
Hs 578T GDSC1 4.6691 6.3845 1.7951 0.4918
MDA-MB-231 GDSC1; CTRP2 4.9346 9.4986 3.3233 13.7597
HCC1954 GDSC1; CTRP2 5.0313 6.6292 1.8429 0.1602
HCC1395 GDSC1; CTRP2 5.1311 8.698 3.8965 14.0581
JIMT-1 GDSC1; CTRP2 5.2255 8.7991 3.9366 10.5764
CAL-120 GDSC1; CTRP2 5.3135 8.903 3.9681 10.247
HCC2218 GDSC1; CTRP2 5.3187 7.6941 4.5574 7.808
T-47D GDSC1; CTRP2 5.323 9.7492 3.5611 11.9085
HCC1428 GDSC1; CTRP2 5.35 6.8488 4.979 6.0282
ZR-75-30 GDSC1; CTRP2 5.3892 8.2044 4.3793 8.3753
ZR-75-1 CTRP2 5.4186 8.4121 4.3057 8.613
HDQ-P1 GDSC1; CTRP2 5.4362 8.9893 4.0388 9.6811
BT-474 GDSC1; CTRP2 5.4739 6.6592 5.1894 4.8719
HCC1500 GDSC1; CTRP2 5.5191 7.1395 5.015 5.4602
HCC202 GDSC1; CTRP2 5.5561 8.5639 4.3577 8.0921
HMC-1-8 CTRP2 5.6212 12.4764 -0.5558 7.5954
HCC1569 GDSC1; CTRP2 5.6824 8.1815 4.6609 8.4162
CAL-148 GDSC1; CTRP2 6.035 7.671 5.2232 4.4561
MDA-MB-157 GDSC1; CTRP2 6.0614 10.2594 3.951 8.7616
KPL-1 CTRP2 6.0844 7.9797 5.1099 3.8516
SK-BR-3 CTRP2 6.1651 9.5346 4.3989 6.6867
HCC1419 GDSC1; CTRP2 6.2022 7.4645 5.4611 2.1636
BT-549 GDSC1; CTRP2 6.3352 8.9462 4.8282 4.5779
HCC1937 GDSC1; CTRP2 6.5785 10.5127 4.2383 8.4866
UACC-812 GDSC1; CTRP2 6.7111 16.3348 1.4437 17.2865
MDA-MB-361 GDSC1; CTRP2 7.2465 12.0638 3.9682 6.6532
AU565 GDSC1; CTRP2 7.3401 11.5491 4.2827 5.2435
CAMA-1 GDSC1; CTRP2 8.2589 14.3714 3.5502 6.863
MCF-7 GDSC1; CTRP2 8.3614 10.1731 5.4484 0.3211
BT 440 CTRP2 3.0286 8.0904 2.0337 23.677
BT 112 CTRP2 3.5303 7.4712 2.8123 19.3675
BT 231 CTRP2 3.6985 8.2012 2.689 19.3732
BT 286 CTRP2 3.7961 6.1715 3.5549 15.8268
BT164 CTRP2 3.9215 8.3586 2.8511 18.1531
BT 145 CTRP2 3.9934 6.7889 3.5662 15.2056
BT 416 CTRP2 4.0014 6.8374 3.5572 15.217
BT 228 CTRP2 4.3347 7.1868 3.7777 13.4429
BT 172 CTRP2 4.4348 8.7264 3.2046 15.4424
BT 271 CTRP2 4.5331 11.641 1.9048 20.2256
BT 428 CTRP2 4.6218 7.2275 4.0625 11.5584
BT 139 CTRP2 4.6532 6.2555 4.4637 9.9403
BT 187 CTRP2 4.677 7.1534 4.1511 11.0641
BT 359 CTRP2 4.6875 7.3703 4.07 11.3538
BT147 CTRP2 4.6877 8.4491 3.5841 13.2934
BT 159 CTRP2 4.7584 7.3362 4.158 10.8205
BT 482 CTRP2 4.8303 11.0226 2.483 17.3509
BT 444 CTRP2 4.8364 7.1951 4.2994 10.058
BT 216 CTRP2 4.9415 8.7015 3.7132 12.1545
BT 340 CTRP2 4.9912 6.9849 4.5498 8.6642
BT 232 CTRP2 4.9967 8.7654 3.7357 11.9324
BT 498 CTRP2 5.0124 8.3316 3.9578 10.9884
BT 239 CTRP2 5.1155 8.9734 3.7485 11.6031
BT 131 CTRP2 5.1646 9.3592 3.6068 12.073
BT 320 CTRP2 5.1653 7.3575 4.5631 8.1608
BT 504 CTRP2 5.1779 10.1982 3.2076 13.6781
BT 328 CTRP2 5.2228 8.4676 4.0947 9.9314
BT 330 CTRP2 5.3018 9.9704 3.4327 12.4836
BT 422 CTRP2 5.3956 9.3621 3.8181 10.6864
BT 248 CTRP2 5.4491 9.0076 4.0415 9.6417
BT 333 CTRP2 5.4609 9.4968 3.8106 10.575
BT 179 CTRP2 5.7369 7.8325 4.8827 5.5107
BT 224 CTRP2 6.1123 10.0956 4.075 8.1449
⏷ Show the Full List of 90 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 5.7401 8.7165 4.447 9.9828
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D-247MG GDSC1 -2.0824 3.9753 -3.0097 53.3958
KS-1 [Human Krukenberg tumour] GDSC1 1.2205 6.0932 -0.5265 25.9839
DK-MG GDSC1; CTRP2 1.2937 10.2556 -0.6841 36.9168
AM-38 GDSC1 1.8025 3.2931 1.3727 10.0248
GI-1 GDSC1 1.9141 9.3955 -1.5384 27.9642
MOG-G-CCM GDSC1 1.9152 3.4621 1.4033 9.2806
D-336MG GDSC1 1.9553 4.4846 0.9418 12.6765
KINGS-1 GDSC1 1.9899 8.4534 -1.0029 25.201
MOG-G-UVW GDSC1 2.2157 6.9474 -0.0575 18.8597
GB-1 GDSC1; CTRP2 2.2265 3.6221 1.6122 4.49
D-566MG GDSC1 2.23 5.099 0.8782 12.0815
H4 GDSC1 2.2526 4.4151 1.2391 9.1876
D-392MG GDSC1 2.2887 9.4635 -1.2539 25.2696
Hs 683 GDSC1; CTRP2 2.306 6.0921 1.9514 26.1312
D-502MG GDSC1 2.3393 6.1192 0.4606 14.804
CAS-1 GDSC1 2.3442 4.7643 1.1421 9.6087
D-423MG GDSC1 2.4226 4.7353 1.2215 8.7043
YH-13 GDSC1; CTRP2 2.4611 8.2641 1.364 27.6727
T98G GDSC1; CTRP2 2.4695 4.6181 2.4202 23.9826
42-MG-BA GDSC1; CTRP2 2.7565 7.1608 2.0996 24.2327
M059J GDSC1 2.8883 5.9211 0.9954 8.9166
SF539 GDSC1; CTRP2 2.9836 8.2914 1.9043 24.271
KNS-60 CTRP2 3.057 4.4566 2.3546 3.6576
Onda 11 GDSC1 3.1351 9.3884 -0.5338 18.5312
Becker GDSC1; CTRP2 3.2057 9.5851 1.5771 24.7978
D-542MG GDSC1 3.2686 6.1355 1.1622 6.5621
KNS-81-FD GDSC1 3.2833 5.53 1.4593 4.3334
KG-1-C CTRP2 3.3437 5.8413 3.1499 18.6653
GaMG GDSC1; CTRP2 3.4993 5.4291 3.4074 17.2699
A-172 GDSC1; CTRP2 3.5662 7.4542 2.857 19.0977
LN-405 GDSC1 3.574 7.496 0.7167 9.0006
KNS-81 CTRP2 3.6099 5.8799 2.0726 3.9501
NMC-G1 GDSC1; CTRP2 3.6246 7.8934 2.7414 19.3749
SNU-1105 CTRP2 3.6716 8.941 2.3383 20.7768
LNZTA3WT4 GDSC1 3.6842 9.0716 0.0305 13.3796
SW1088 GDSC1; CTRP2 3.707 8.3155 2.6488 19.5038
D-263MG GDSC1 3.7797 5.3586 1.8101 1.1605
PFSK-1 GDSC1 3.8678 8.1788 0.5878 9.1365
DBTRG-05MG GDSC1; CTRP2 3.8711 8.3087 2.8211 18.4028
U-118MG GDSC1; CTRP2 3.8805 11.0888 1.5511 23.0938
YKG-1 GDSC1; CTRP2 3.897 7.2378 3.2935 16.5126
M059K CTRP2 3.9231 6.7661 3.4987 15.6611
SNU-738 CTRP2 3.9958 7.9608 3.1001 16.9892
Onda 10 GDSC1 4.066 5.9921 1.6883 1.4569
SNU-201 CTRP2 4.0802 7.5836 3.3473 15.8024
SK-MG-1 GDSC1 4.2581 6.453 1.592 1.7334
GMS-10 CTRP2 4.3489 6.8074 3.9413 12.7764
SW1783 GDSC1; CTRP2 4.445 7.4054 3.8032 13.0452
GOS-3 CTRP2 4.6598 9.4199 3.0989 15.3142
D283 Med GDSC1; CTRP2 4.678 8.762 3.4282 13.9452
CCF-STTG1 CTRP2 4.7259 10.8631 2.464 17.666
SNB-75 GDSC1; CTRP2 4.7622 7.1175 4.2552 10.4287
TM-31 CTRP2 4.8643 7.4163 4.2317 10.2525
KALS-1 GDSC1; CTRP2 5.0066 7.9409 4.1359 10.2786
SF126 GDSC1; CTRP2 5.0184 9.8267 0.537 4.9827
8-MG-BA GDSC1; CTRP2 5.0949 8.5513 3.9326 10.8956
ONS-76 GDSC1; CTRP2 5.1095 8.088 4.1676 9.9001
SF268 GDSC1; CTRP2 5.1235 7.9701 4.2369 9.5841
SNU-489 CTRP2 5.1822 9.5284 3.5403 12.3067
U-251MG GDSC1; CTRP2 5.1887 9.4184 3.6002 12.046
SNU-626 CTRP2 5.3019 14.405 1.2303 20.8477
LN-18 GDSC1; CTRP2 5.5175 7.7491 4.7211 8.5663
SNU-466 CTRP2 6.0072 7.036 5.5173 3.1199
LN-229 GDSC1; CTRP2 6.1075 8.2964 4.9705 5.6422
SF295 GDSC1; CTRP2 6.2408 12.1822 3.1376 14.9273
U-87MG ATCC GDSC1; CTRP2 6.306 15.2975 1.634 17.3948
KNS-42 GDSC1; CTRP2 7.0736 15.0521 2.3669 13.2919
Daoy GDSC1; CTRP2 7.7803 15.8046 -0.567 6.2569
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC1 2.2424 10.0647 -1.5933 26.9528
TGBC1TKB GDSC1 3.261 5.4766 1.4701 4.3082
ETK-1 GDSC1 3.7251 10.1545 -0.4694 16.3303
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2 1.1781 3.6819 0.4383 11.9698
MFE-280 GDSC1 1.5871 4.9369 0.3797 18.4503
AN3-CA GDSC1; CTRP2 2.1676 5.815 1.8739 26.8356
JHUEM-7 CTRP2 2.3095 5.8299 2.0249 25.8629
RL95-2 GDSC1; CTRP2 2.6036 5.1914 2.4831 23.3342
JHUEM-3 CTRP2 3.3223 6.9269 2.7933 20.0325
MFE-296 GDSC1; CTRP2 3.6936 6.8135 3.2342 17.3136
HEC-108 CTRP2 3.7771 5.7027 1.4026 1.0588
HEC-59 CTRP2 3.7885 5.3077 1.5629 0.5013
HEC-265 CTRP2 3.826 4.9193 1.7183 0.1304
HEC-6 CTRP2 4.1938 5.4959 1.6515 0.1471
HEC-251 CTRP2 4.4264 6.0536 1.5418 0.2731
JHUEM-1 CTRP2 4.4355 6.0698 4.2816 11.2576
EN GDSC1; CTRP2 4.6503 9.6762 2.9671 15.8642
ESS-1 GDSC1; CTRP2 4.7811 6.6451 4.4653 9.5655
HEC-151 CTRP2 4.7849 5.9357 4.698 8.6924
HEC-50B CTRP2 4.9609 7.4271 4.3252 9.6318
HEC-1-A CTRP2 5.1625 7.4103 4.5362 8.2762
MFE-319 GDSC1; CTRP2 6.0177 7.7977 5.1454 3.8306
EFE-184 CTRP2 6.0909 8.4903 4.86 4.8895
KLE GDSC1; CTRP2 8.213 10.9441 5.0788 1.7119
HEC-1-B CTRP2 8.3327 10.3239 5.3807 0.4649
Ishikawa (Heraklio) 02 ER- CTRP2 3.0156 6.8999 0.3909 7.3681
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB1047-RCC GDSC1 1.4355 2.8629 1.1788 13.27
CAL-54 GDSC1; CTRP2 1.9542 3.554 1.949 27.2668
RXF 393L GDSC1 2.0313 5.4767 0.5175 15.5754
HA7-RCC GDSC1 2.2522 3.9428 1.4746 7.3382
KTCTL-21 GDSC1 2.2525 4.7472 1.0732 10.4861
NCC021 GDSC1 2.3588 6.501 0.2859 15.9818
A-704 GDSC1 2.3732 3.7072 1.6948 5.1542
KTCTL-26A GDSC1 2.538 3.9521 1.7042 4.5196
BB65-RCC GDSC1 2.61 4.9915 1.2435 7.8908
KTCTL-1M GDSC1 2.6209 4.4806 1.5057 5.8065
KTCTL-140 GDSC1 2.9189 5.1688 1.3868 5.829
KTCTL-195 GDSC1 2.9299 6.197 0.8904 9.5825
TK-10 GDSC1 3.0568 5.2002 1.4672 4.841
769-P GDSC1; CTRP2 3.0596 4.3974 1.845 1.4726
UO-31 GDSC1; CTRP2 3.1802 5.7732 2.9883 19.7468
SW156 GDSC1 3.226 7.0502 0.6886 10.183
LB996-RCC GDSC1 3.2555 5.4366 1.4854 4.2099
LB2241-RCC GDSC1 3.6289 6.169 1.377 4.1437
BFTC-909 GDSC1 3.6399 6.2168 1.3618 4.2263
SN12C GDSC1 3.7389 5.5442 1.7136 1.7504
VMRC-RCW GDSC1; CTRP2 4.2464 8.4845 3.1261 16.231
KMRC-20 GDSC1; CTRP2 4.3483 6.9932 3.8692 13.0531
OS-RC-2 GDSC1; CTRP2 4.5574 8.2309 3.5546 13.737
ACHN GDSC1; CTRP2 4.6446 7.4021 4.0118 11.6962
SW13 GDSC1 4.8519 6.3211 1.8847 0.1977
KMRC-1 GDSC1; CTRP2 4.86 6.9789 4.4155 9.5404
KTCTL-13 GDSC1 4.8762 6.6507 1.7787 0.436
Caki-1 GDSC1; CTRP2 4.8858 8.1036 3.9407 11.3654
A-498 GDSC1; CTRP2 4.9282 7.129 4.4228 9.3301
Caki-2 CTRP2 4.9609 8.5557 3.8014 11.7489
KMRC-2 CTRP2 4.9967 9.2586 3.4982 12.9029
786-O GDSC1; CTRP2 5.0469 9.0169 3.6625 12.1144
VMRC-RCZ GDSC1; CTRP2 5.1495 8.7658 3.8811 10.9794
TUHR4TKB CTRP2 5.2561 8.5058 4.1078 9.8005
TUHR10TKB CTRP2 5.3587 7.2797 4.7916 6.7585
TUHR14TKB CTRP2 5.7462 9.6238 4.0005 9.1819
RCC10RGB GDSC1; CTRP2 6.1524 10.5045 3.9037 8.7857
SNU-1272 CTRP2 7.9813 15.4921 2.8213 13.2582
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H716 GDSC1; CTRP2 0.6809 4.3709 0.5485 36.1462
KM12 GDSC1; CTRP2 1.0513 9.343 -0.5599 37.4914
SNU-175 GDSC1; CTRP2 2.2121 4.5113 2.1597 25.7077
NCI-H747 GDSC1; CTRP2 2.2818 4.1683 2.2606 25.1378
SW48 GDSC1; CTRP2 2.2841 3.2172 2.284 25.0518
HCT 116 GDSC1; CTRP2 2.3449 3.8574 1.5961 4.2642
HT-29 GDSC1; CTRP2 2.3962 4.2115 1.4616 4.8834
SNU-1040 GDSC1 2.4324 5.0663 1.0641 9.8996
GP2d CTRP2 2.568 7.0855 1.9226 25.428
SW948 GDSC1; CTRP2 2.6218 4.3941 2.599 22.8783
LoVo GDSC1; CTRP2 2.8249 5.3675 2.6899 21.9113
COLO 320HSR GDSC1 2.8415 4.5387 1.6381 4.1281
CL-34 CTRP2 2.8943 20.0519 -5.579 32.8338
LS180 GDSC1; CTRP2 2.9331 5.008 1.4748 3.6164
SW1417 GDSC1; CTRP2 3.0947 5.5259 2.9506 20.1469
COLO205 GDSC1; CTRP2 3.2315 4.3111 3.2283 18.7504
SW837 GDSC1 3.2331 6.8938 0.7702 9.5664
SW620 GDSC1; CTRP2 3.2508 6.1272 2.9726 19.5865
HCT 15 GDSC1; CTRP2 3.2717 5.4602 3.1556 18.8701
HCC2998 GDSC1 3.2783 5.505 1.4679 4.2833
CaR-1 GDSC1 3.4328 5.4208 1.6009 3.0035
T84 GDSC1; CTRP2 3.4379 5.8238 3.2569 17.9926
HT-55 GDSC1; CTRP2 3.4992 4.9532 3.4715 17.0499
CL-11 GDSC1; CTRP2 3.5248 5.5718 3.4078 17.1881
LS513 GDSC1; CTRP2 3.5474 4.7349 3.5368 16.6709
SNU-407 GDSC1; CTRP2 3.6449 5.7764 3.4938 16.5086
COLO 320 CTRP2 3.7283 6.3417 3.4298 16.4865
OUMS-23 CTRP2 3.7457 5.8249 3.5921 15.8469
MDST8 GDSC1; CTRP2 3.7693 6.8826 3.291 16.8829
SK-CO-1 CTRP2 3.8231 5.7713 3.689 15.2623
SNU-C5 GDSC1; CTRP2 3.8457 6.1446 3.6167 15.4524
SNU-C2B GDSC1 3.8973 6.5445 1.3641 3.6918
LS123 GDSC1; CTRP2 3.9241 7.3666 3.2714 16.5218
SW626 GDSC1 3.9298 9.4814 0.0045 12.857
RKO GDSC1; CTRP2 3.9605 7.1235 3.4057 15.907
GP5d GDSC1 3.9944 11.5524 -0.9584 18.2384
CCK-81 GDSC1 4.0092 5.9245 1.6889 1.5235
C2BBe1 GDSC1; CTRP2 4.0519 6.3304 3.7856 14.2181
SNU-C1 GDSC1; CTRP2 4.1265 5.9054 3.9876 13.2599
LS1034 GDSC1; CTRP2 4.1357 6.2901 3.8895 13.5876
SNU-61 GDSC1; CTRP2 4.1603 6.2894 3.9164 13.4154
LS411N GDSC1; CTRP2 4.2955 5.2851 4.2774 11.7123
SNU-503 CTRP2 4.3182 8.1068 3.3682 15.0899
SW1116 GDSC1 4.3985 6.6487 1.5789 1.6327
COLO 678 GDSC1; CTRP2 4.4416 7.0885 3.9303 12.5606
SNU-81 GDSC1 4.4429 6.1626 1.7869 0.6574
CW-2 GDSC1; CTRP2 4.4525 7.4863 3.7767 13.1288
HCC-56 CTRP2 4.4878 6.478 4.2102 11.3654
SW1463 GDSC1 4.5315 6.2193 1.8014 0.5494
HT115 GDSC1; CTRP2 4.6303 6.5335 4.3446 13.4209
NCI-H508 CTRP2 4.709 6.9329 4.2755 10.4939
HCT 8 CTRP2 4.8042 6.0694 4.684 8.6834
DLD-1 CTRP2 4.8293 11.526 2.2351 18.3038
SNU-C2A CTRP2 5.0386 13.4889 -1.3949 12.3381
RCM-1 [Human ESC] GDSC1; CTRP2 5.8389 8.6638 4.5597 6.6487
SNU-C4 CTRP2 6.1045 7.7739 5.2292 3.3125
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 3.7284 7.0058 1.0512 6.2191
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuH-6 CTRP2 0.7667 6.8912 0.033 37.2082
SNU-182 CTRP2 1.3999 9.718 -2.3256 24.7988
Li-7 CTRP2 2.2984 8.538 1.082 29.084
HLE GDSC1 2.6849 5.18 1.208 7.9231
JHH-7 GDSC1 2.748 4.5951 1.5441 5.117
Hep 3B2.1-7 GDSC1; CTRP2 2.8633 4.5569 2.8389 21.2749
SNU-878 CTRP2 2.9338 4.8979 2.8803 20.9042
JHH-2 GDSC1; CTRP2 3.2739 5.9728 3.0401 19.2728
JHH-4 GDSC1; CTRP2 3.3472 10.7872 1.1707 25.778
SNU-761 CTRP2 3.3707 5.5541 2.0564 4.5147
Huh-7 GDSC1 3.4017 5.4144 1.5855 3.1729
JHH-5 CTRP2 3.4892 6.5195 3.113 18.3603
HuH-1 GDSC1; CTRP2 3.5901 5.348 3.5189 16.5932
SNU-475 GDSC1; CTRP2 3.9381 6.978 3.4371 15.8508
Hep-G2/C3A GDSC1 4.0594 5.2983 1.9517 0.3356
SNU-387 GDSC1; CTRP2 4.0638 11.1171 1.7141 22.0572
SNU-449 GDSC1; CTRP2 4.0659 6.1059 3.8681 13.8749
SNU-423 GDSC1; CTRP2 4.321 8.0746 3.3853 15.0153
HLF CTRP2 4.5779 6.708 4.224 11.056
JHH-1 GDSC1; CTRP2 4.7009 7.2881 4.1191 11.1253
Hep-G2 CTRP2 4.9448 7.7547 4.1605 10.3325
SK-HEP-1 GDSC1; CTRP2 5.0462 7.6606 4.305 9.4974
PLC/PRF/5 CTRP2 5.321 6.8556 4.9463 6.233
JHH-6 GDSC1; CTRP2 6.0441 6.8787 5.627 1.7548
SNU-398 GDSC1; CTRP2 6.8231 10.7624 4.2987 5.9627
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 210 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EBC-1 GDSC1 -1.5186 4.2824 -2.5195 48.9989
NCI-H1703 GDSC1; CTRP2 -0.0539 8.0592 -1.2525 42.8343
NCI-H2731 GDSC1 0.4107 2.8808 0.0697 26.5461
LC-2/ad GDSC1 1.4957 5.245 0.1442 20.5108
NCI-H1184 CTRP2 1.5144 5.4339 1.253 31.049
NCI-H1755 GDSC1; CTRP2 1.5765 8.5829 0.2992 33.6789
NCI-H1048 GDSC1 1.5854 6.0069 -0.1456 22.0279
NCI-H1693 GDSC1; CTRP2 1.6379 6.8246 1.0018 31.4425
NCI-H847 GDSC1 1.6805 3.7514 1.0383 13.1247
NCI-H1341 CTRP2 1.7243 4.3746 1.659 29.0006
COLO 699 CTRP2 1.7869 9.4724 -1.8695 21.8469
RERF-LC-MS GDSC1; CTRP2 1.8145 7.1139 1.0974 30.5629
NCI-H2795 GDSC1 1.8438 3.014 1.5414 8.5588
Lu-135 GDSC1 1.8518 2.9417 1.5817 8.2193
DMS 273 GDSC1; CTRP2 1.9658 6.2662 1.5308 28.6527
SBC-3 GDSC1 2.0535 3.1461 1.6874 6.4831
NCI-H2227 GDSC1 2.0638 3.6769 1.4387 8.3683
IST-SL1 GDSC1 2.0729 3.5754 1.497 7.8765
NCI-H2869 GDSC1 2.0853 3.6021 1.4952 7.8389
HCC44 GDSC1; CTRP2 2.1707 4.6991 1.0268 7.8961
UMC-11 GDSC1 2.2021 3.5132 1.6447 6.1952
COR-L51 CTRP2 2.232 4.9675 2.1206 25.7771
NCI-H810 GDSC1; CTRP2 2.2537 4.76 2.1743 25.5229
NCI-H1781 GDSC1 2.2724 3.1801 1.8725 4.1288
NCI-H2803 GDSC1 2.2895 5.5808 0.688 13.3059
CAL-12T GDSC1; CTRP2 2.3028 16.595 -4.8078 30.7026
NCI-H1688 GDSC1 2.3461 5.7658 0.6429 13.4334
NCI-H2085 GDSC1; CTRP2 2.4397 4.3219 2.4146 24.0993
SBC-5 GDSC1; CTRP2 2.4471 6.1069 0.556 9.786
NCI-H1975 GDSC1; CTRP2 2.4541 4.1523 2.4394 23.968
NCI-H510A GDSC1 2.5126 3.7769 1.7715 4.0743
NCI-H2595 GDSC1 2.5759 6.5981 0.4154 14.2729
NCI-H1648 GDSC1 2.5823 4.7516 1.3412 7.2189
NCI-H1770 GDSC1 2.6427 4.0374 1.7407 3.9095
EMC-BAC-2 GDSC1 2.6451 4.1377 1.6932 4.2701
PC-14 GDSC1; CTRP2 2.68 4.0797 2.2033 5.4501
COR-L23 GDSC1 2.6924 4.4295 1.5846 4.9702
NCI-H1155 GDSC1; CTRP2 2.7009 5.5087 2.5266 22.8746
NCI-H2373 GDSC1 2.703 5.3005 1.1621 8.2205
NCI-H596 GDSC1 2.7106 4.6921 1.4688 5.8137
LXF 289 GDSC1; CTRP2 2.7118 4.0861 2.7058 22.2221
EMC-BAC-1 GDSC1 2.7332 6.1375 0.7697 11.1244
NCI-H2228 GDSC1; CTRP2 2.743 4.6182 1.9992 6.3282
Calu-3 GDSC1; CTRP2 2.7493 5.949 0.876 7.2916
NCI-H3122 GDSC1 2.7792 4.7061 1.5124 5.2691
NCI-H446 GDSC1; CTRP2 2.7799 4.6767 2.7414 21.8783
NCI-H345 GDSC1 2.7986 5.0238 1.3707 6.306
ABC-1 GDSC1 2.8029 8.9888 -0.5956 20.0021
NCI-H2135 GDSC1 2.8168 7.0167 0.3978 13.5712
EPLC-272H GDSC1; CTRP2 2.8216 6.5122 2.3893 22.9931
NCI-H520 GDSC1; CTRP2 2.8317 6.6817 2.3456 23.1205
NCI-H23 GDSC1; CTRP2 2.8483 6.3251 2.4758 22.6005
NCI-H2591 GDSC1 2.8705 5.3278 1.2741 6.8349
NCI-H2804 GDSC1 2.874 5.3888 1.2467 7.035
NCI-H2030 GDSC1; CTRP2 2.8838 5.094 1.3982 4.1301
LK-2 GDSC1 2.8881 4.6749 1.6045 4.2556
NCI-H2347 GDSC1 2.8912 10.9023 -1.4796 24.1812
NCI-H2171 GDSC1; CTRP2 2.9209 4.4067 2.9077 20.8536
NCI-H64 GDSC1 2.9209 4.1174 1.8898 2.0656
HCC15 GDSC1; CTRP2 2.9223 4.5652 2.8996 20.876
NCI-H2722 GDSC1 2.9562 4.7199 1.6292 3.8895
NCI-H2087 GDSC1 2.9918 5.7327 1.1638 7.3207
Lu-165 GDSC1 2.9968 4.9119 1.5647 4.2666
Ms-1 GDSC1 3.0021 4.9793 1.536 4.4683
NCI-H2081 GDSC1; CTRP2 3.0141 6.3061 2.6623 21.4255
Sq-1 CTRP2 3.0176 8.3797 1.9034 24.1769
HCC1588 CTRP2 3.033 8.8698 -0.5642 12.4546
COR-L105 GDSC1; CTRP2 3.0614 7.4504 2.3203 22.5373
MOR/CPR CTRP2 3.0858 5.2437 1.2289 2.7073
Lu-99A GDSC1 3.0869 5.2425 1.4672 4.7625
NCI-H2009 GDSC1; CTRP2 3.0877 5.591 2.9292 20.244
NCI-H1437 GDSC1 3.1066 5.2643 1.4699 4.6915
NCI-H841 GDSC1; CTRP2 3.1106 6.4643 2.7189 20.9298
NCI-H1581 GDSC1; CTRP2 3.1349 7.314 2.4503 21.8462
Lu-139 GDSC1 3.1376 5.0912 1.5721 3.8595
NCI-H1876 GDSC1 3.1395 8.5191 -0.0994 15.8724
A-427 GDSC1 3.198 6.5235 0.9255 8.52
HCC827 GDSC1; CTRP2 3.222 6.7142 0.8498 6.4146
NCI-H2369 GDSC1 3.2523 4.7143 1.8136 1.9229
COR-L321 GDSC1 3.3081 5.5026 1.4878 4.0695
NCI-H1435 GDSC1; CTRP2 3.3213 5.9674 3.0932 18.937
RERF-LC-KJ GDSC1 3.3719 6.415 1.0981 6.7645
SBC-1 GDSC1 3.3748 5.2753 1.6327 2.9028
NCI-H647 GDSC1; CTRP2 3.3787 5.579 3.2479 18.2091
HARA [Human squamous cell lung carcinoma] GDSC1; CTRP2 3.3968 6.2209 3.105 18.6652
DV-90 CTRP2 3.4437 4.888 3.419 17.4091
NCI-H1436 GDSC1 3.4442 10.9857 -1.0888 20.5395
A-549 GDSC1; CTRP2 3.4552 4.8408 3.4347 17.3184
NCI-H2106 CTRP2 3.5123 5.7533 3.3547 17.4143
HCC33 GDSC1 3.5263 5.4915 1.6228 2.6741
SK-LU-1 GDSC1; CTRP2 3.5415 6.6521 3.1257 18.1597
VMRC-LCD CTRP2 3.5731 5.6628 3.4412 16.9185
LCLC-97TM1 GDSC1; CTRP2 3.594 6.7483 3.1495 17.9181
HCC1833 CTRP2 3.617 8.81 -0.1138 8.8591
HCC78 GDSC1; CTRP2 3.6378 7.3403 2.9778 18.4393
COR-L311 GDSC1 3.6411 7.7868 0.6227 9.4871
NCI-H322M GDSC1 3.6418 5.8777 1.5163 3.1652
Lu-99 CTRP2 3.6574 5.9109 3.4746 16.5385
SW1271 GDSC1; CTRP2 3.71 6.8081 1.6909 5.7133
NCI-H2172 GDSC1 3.7139 6.9225 1.081 6.0417
Lu-134-A GDSC1 3.7268 7.3239 0.9006 7.2939
NCI-H2110 GDSC1; CTRP2 3.7316 6.8102 3.2764 17.0458
RERF-LC-Sq1 GDSC1 3.744 8.577 0.3127 11.3471
NCI-H720 GDSC1 3.7584 5.038 1.9268 0.6273
NCI-H1915 GDSC1; CTRP2 3.7625 6.2526 3.4942 16.1488
NCI-H2405 GDSC1; CTRP2 3.765 6.8605 3.2944 16.8827
LOU-NH91 GDSC1; CTRP2 3.7723 6.4092 3.4564 16.2579
CPC-N GDSC1 3.774 8.6449 0.3006 11.3459
PaCa-3 GDSC1 3.7793 7.2995 0.946 6.8441
NCI-H1650 GDSC1; CTRP2 3.7871 7.2782 3.1609 17.3252
NCI-H2170 GDSC1; CTRP2 3.8166 4.8902 3.8065 14.8759
RERF-LC-A1 CTRP2 3.8458 18.135 -4.5345 25.6559
SW1573 GDSC1; CTRP2 3.8549 8.4558 2.7401 18.7581
DMS 454 CTRP2 3.8759 7.0426 3.3461 16.3717
SHP-77 GDSC1; CTRP2 3.8837 5.8986 3.7245 14.9479
NCI-H838 GDSC1; CTRP2 3.8906 6.5429 3.541 15.5973
LC-1/sq GDSC1 3.8918 7.3974 0.9714 6.4008
COR-L303 GDSC1 3.8986 5.3992 1.848 0.8486
NCI-H1568 GDSC1; CTRP2 3.9573 5.3962 3.9053 14.0812
NCI-H1836 GDSC1 3.9635 5.7824 1.725 1.3871
HOP-92 GDSC1; CTRP2 3.9669 7.1132 3.4165 15.848
NCI-H2444 GDSC1; CTRP2 3.9888 5.8393 2.341 1.9941
NCI-H82 GDSC1 4.0064 5.7234 1.7686 1.1157
NCI-H661 GDSC1; CTRP2 4.0068 7.5978 3.2646 16.3216
NCI-H358 GDSC1; CTRP2 4.0188 8.0346 3.0923 16.9582
Calu-6 GDSC1; CTRP2 4.0684 7.2569 3.468 15.3688
Lu-65 GDSC1; CTRP2 4.1 10.3527 2.1134 20.5122
NCI-H1694 GDSC1; CTRP2 4.1447 5.7895 4.0349 13.0351
NCI-H1573 GDSC1 4.1498 6.2578 1.6199 1.7192
NCI-H226 GDSC1; CTRP2 4.1516 6.2199 2.2644 2.1229
LCLC-103H GDSC1; CTRP2 4.1561 7.4769 3.4712 15.1161
NCI-H2342 GDSC1; CTRP2 4.1803 6.7709 3.7739 13.8885
ChaGo-K-1 GDSC1; CTRP2 4.201 6.1587 4.0003 12.9872
SK-MES-1 GDSC1; CTRP2 4.2149 5.5451 4.1586 12.3802
HCC1195 CTRP2 4.2298 8.6082 3.0535 16.5597
HCC366 CTRP2 4.2329 6.7679 3.8316 13.5209
NCI-H1793 GDSC1; CTRP2 4.2462 7.2301 3.6668 14.1136
NCI-H187 GDSC1 4.2638 5.7717 1.8595 0.5165
COR-L95 GDSC1; CTRP2 4.3113 6.86 3.8811 13.1112
NCI-H292 GDSC1; CTRP2 4.3598 9.5084 2.7656 22.0917
NCI-H522 GDSC1; CTRP2 4.3796 7.4064 3.7345 13.4888
LK2 CTRP2 4.3812 5.3432 4.3621 11.1448
NCI-H1373 CTRP2 4.4235 8.5848 3.2586 15.256
NCI-H2196 GDSC1; CTRP2 4.4484 9.6303 2.7942 17.0368
NCI-H2291 GDSC1; CTRP2 4.4627 7.0936 3.9506 15.9533
EKVX GDSC1; CTRP2 4.4659 7.3818 3.835 12.8649
NCI-H1963 GDSC1 4.4674 6.8054 1.5479 1.7125
DMS 53 GDSC1; CTRP2 4.484 6.2793 4.272 11.1472
NCI-H727 GDSC1; CTRP2 4.5153 6.2077 4.3283 10.8476
NCI-H748 GDSC1 4.5215 6.6712 1.6259 1.2686
NCI-H441 GDSC1 4.5459 6.5793 1.6722 1.0375
DMS 79 GDSC1; CTRP2 4.5773 6.1268 1.8524 0.2614
HCC2108 CTRP2 4.604 11.4128 -0.6956 9.9176
LUDLU-1 CTRP2 4.6084 7.2889 4.0227 11.7497
HOP-62 GDSC1; CTRP2 4.6304 7.8241 3.812 12.5241
NCI-H3255 GDSC1 4.6503 6.3158 1.8126 0.4484
HCC95 CTRP2 4.6679 7.0186 4.1974 10.9085
NCI-H524 GDSC1 4.6733 6.4556 1.7709 0.5665
NCI-H2023 GDSC1; CTRP2 4.6906 9.0546 3.3025 14.4216
NCI-H146 CTRP2 4.7295 6.7267 4.3788 10.0401
NCI-H1092 GDSC1; CTRP2 4.7834 8.368 3.7164 12.5239
NCI-H2141 GDSC1; CTRP2 4.7877 8.8269 3.5046 13.3705
NCI-H460 GDSC1; CTRP2 4.7996 7.5344 4.1133 10.8901
T3M-10 CTRP2 4.8019 7.3317 4.2047 10.5221
NCI-H1666 GDSC1 4.8073 6.8952 1.6621 0.8677
NCI-H1395 CTRP2 4.8228 8.5627 3.6637 12.641
NCI-H1304 GDSC1 4.8232 6.1156 1.944 0.11
NCI-H1869 GDSC1; CTRP2 4.8265 7.2128 4.2815 10.1545
NCI-H889 CTRP2 4.8315 9.2731 3.3341 13.9573
NCI-H1993 GDSC1 4.8616 15.0678 -2.052 20.9196
NCI-H1944 GDSC1; CTRP2 4.9384 7.9125 4.0815 10.6668
DMS 114 GDSC1; CTRP2 4.9412 7.566 4.2428 10.0113
IA-LM GDSC1; CTRP2 4.9514 7.9621 4.0713 10.6758
HCC1438 CTRP2 5.0529 7.7094 4.2892 9.5447
NCI-H513 GDSC1 5.0575 7.0695 1.6978 0.5838
NCI-H2818 GDSC1 5.0615 6.6983 1.83 0.2433
Calu-1 CTRP2 5.0673 6.7546 4.7257 7.773
NCI-H1355 GDSC1; CTRP2 5.0804 8.934 3.7344 11.7421
HCC1171 CTRP2 5.0899 13.126 -1.1889 11.3348
NCI-H2461 GDSC1 5.1193 7.6079 1.5227 1.1826
COLO 668 GDSC1; CTRP2 5.1339 10.3301 3.1024 14.2029
NCI-H650 GDSC1; CTRP2 5.217 9.2653 3.7014 11.5656
NCI-H1339 CTRP2 5.2179 7.2294 4.6743 7.5819
NCI-H1651 GDSC1; CTRP2 5.2305 7.9907 4.331 8.9439
NCI-H1734 GDSC1; CTRP2 5.2502 8.9005 3.9104 13.6314
NCI-H1105 CTRP2 5.2662 11.3689 2.7088 15.489
NCI-H2029 GDSC1; CTRP2 5.3301 8.1389 4.3553 8.6104
RERF-LC-Ad2 CTRP2 5.3427 8.7843 4.0533 9.8288
NCI-H1792 GDSC1; CTRP2 5.4045 11.4842 2.7744 14.9301
NCI-H1563 GDSC1; CTRP2 5.4505 8.9094 4.0912 9.4322
NCI-H322 CTRP2 5.5376 8.1404 4.549 7.3373
NCI-H1623 GDSC1; CTRP2 5.5382 8.5598 4.3434 8.1907
NCI-H1299 GDSC1; CTRP2 5.5727 9.507 3.9058 9.9395
HCC2935 CTRP2 5.6421 8.849 4.2942 8.1716
NCI-H2126 CTRP2 5.6874 8.6703 4.4233 7.5358
NCI-H2122 GDSC1; CTRP2 5.7616 8.7809 4.4339 7.3356
HCC4006 CTRP2 5.7756 10.077 3.7999 9.9591
HCC2279 CTRP2 5.8426 14.5422 -1.3722 10.8604
COR-L88 GDSC1; CTRP2 5.8809 11.8922 2.9831 13.1068
LC-1/sq-SF CTRP2 5.9447 7.3851 5.2892 3.372
NCI-H211 GDSC1; CTRP2 6.0705 13.4841 -0.5016 8.2126
RERF-LC-Ad1 CTRP2 6.1836 9.0043 4.6788 7.4648
NCI-H526 GDSC1; CTRP2 6.3293 9.176 4.7092 6.5304
KNS-62 CTRP2 6.4642 9.874 4.4672 5.8618
NCI-H69 GDSC1; CTRP2 6.7181 9.8414 4.6739 5.8843
NCI-H209 GDSC1; CTRP2 6.7829 25.2565 -5.1143 24.6808
NCI-H196 GDSC1; CTRP2 7.0464 17.5018 1.1279 21.4234
BEN GDSC1; CTRP2 7.1799 8.1835 5.7092 0.2432
NCI-H1838 GDSC1; CTRP2 8.3268 10.743 5.2152 1.1123
Hs 888.Lu CTRP2 3.7609 11.4683 1.2548 24.4086
⏷ Show the Full List of 210 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 3.7033 12.1653 -1.476 21.6079
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -2.7891 8.525 -4.3715 55.4887
A2780 GDSC1 1.474 4.6609 0.4057 18.7725
ES-2 GDSC1 2.0266 5.3007 0.601 14.9756
OVKATE GDSC1 2.2972 7.6595 -0.3448 20.3599
IGROV-1 GDSC1; CTRP2 2.6277 6.2912 2.2454 24.0983
Caov-4 GDSC1 2.6739 6.7696 0.4083 13.9819
ES2 CTRP2 2.7363 5.0104 1.1116 3.9602
DOV13 GDSC1; CTRP2 3.0345 5.118 1.4914 3.3344
OVISE GDSC1; CTRP2 3.1471 4.5869 1.8106 1.5145
Caov-3 GDSC1; CTRP2 3.2589 6.6067 2.8342 20.0671
OV7 CTRP2 3.4732 8.4253 2.3595 21.2333
COV434 CTRP2 3.498 6.1828 3.2264 17.919
OAW28 GDSC1; CTRP2 3.5223 7.8789 2.6399 20.042
RMG-I GDSC1; CTRP2 3.7222 7.0247 3.1882 17.4046
JHOC-5 CTRP2 3.8413 5.2792 1.5953 0.3833
OVK18 GDSC1; CTRP2 3.8774 5.409 3.8178 14.6397
FU-OV-1 GDSC1; CTRP2 3.8861 7.475 3.1877 16.9478
OV-90 GDSC1; CTRP2 4.094 6.3572 3.8229 13.956
SNU-119 CTRP2 4.2373 6.0649 1.4637 0.5373
Kuramochi GDSC1; CTRP2 4.3619 7.0278 3.8701 13.012
HEY A8 CTRP2 4.3909 6.8318 3.977 12.5222
JHOS-2 GDSC1; CTRP2 4.4098 8.988 3.0586 16.0857
ONCO-DG-1 CTRP2 4.4538 6.6977 4.0947 11.8975
COV644 CTRP2 4.4887 7.4562 3.8272 12.8346
SNU-840 CTRP2 4.4921 8.0966 3.5495 13.9237
TOV-112D GDSC1; CTRP2 4.5189 6.9 4.0872 11.7435
OVCAR-4 GDSC1; CTRP2 4.5632 7.5075 3.8823 12.4206
JHOM-1 CTRP2 4.6595 7.2246 4.103 11.299
OVCAR-3 GDSC1 4.6601 6.3464 1.8053 0.4652
OC 314 GDSC1; CTRP2 4.6675 6.9497 4.2249 10.8032
OAW42 GDSC1; CTRP2 4.6883 5.7938 4.6246 9.2533
SK-OV-3 GDSC1; CTRP2 4.8463 7.2706 4.277 10.1203
MCAS CTRP2 4.9082 8.9562 3.5594 12.8603
TYK-nu GDSC1; CTRP2 4.9823 8.2164 3.9829 10.9588
OVTOKO GDSC1; CTRP2 5.1286 8.039 4.2093 9.684
TOV-21G GDSC1; CTRP2 5.2139 7.6792 4.4623 8.4482
COV362 CTRP2 5.2575 8.0547 4.3265 8.8984
OVCAR-8 GDSC1; CTRP2 5.2987 9.3811 3.7201 11.3056
EFO-21 GDSC1; CTRP2 5.3496 6.6511 5.0642 5.6927
EFO-27 GDSC1; CTRP2 5.4155 7.8708 4.5657 7.5459
SNU-8 CTRP2 5.4251 9.7666 3.645 11.3393
OV56 GDSC1; CTRP2 5.6089 6.9136 5.2091 4.4529
OVSAHO CTRP2 5.9281 8.8297 4.5537 6.494
OVCAR-5 GDSC1; CTRP2 6.7463 10.2011 4.518 5.1812
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 -1.5662 6.6233 -2.4263 50.5371
Aska-SS CTRP2 -1.0417 2.8634 -1.1065 47.2901
A-204 GDSC1; CTRP2 -2.1773 10.2261 -4.3373 52.7739
Tm87-16 CTRP2 0.2894 4.6758 0.0775 38.9367
G-402 GDSC1; CTRP2 0.5048 7.9261 -0.6023 39.5711
TTC-709 CTRP2 1.6949 6.236 1.244 30.4819
EW-8 GDSC1 1.8706 2.9306 1.6059 7.9481
G-401 GDSC1; CTRP2 1.8889 4.9628 1.7523 28.1465
Hs 633.T GDSC1 2.2013 2.985 1.9048 4.163
Rh41 GDSC1; CTRP2 2.2672 3.4539 2.2662 25.1673
TE 441.T GDSC1; CTRP2 2.4549 3.9209 2.4488 23.9344
VA-ES-BJ GDSC1 2.7028 4.1987 1.7053 4.0052
SK-LMS-1 GDSC1; CTRP2 2.7798 8.721 1.5123 26.2292
BT-16 CTRP2 3.1777 5.4107 3.0633 19.49
SW872 GDSC1 3.3272 5.2018 1.638 2.9637
KYM-1 GDSC1; CTRP2 3.759 5.9044 3.587 15.8238
TE 617.T CTRP2 3.8067 6.2883 3.5316 15.8801
SW684 GDSC1 3.8653 5.0478 1.967 0.3956
MES-SA GDSC1; CTRP2 3.9086 5.2982 3.8668 14.3703
SW982 GDSC1; CTRP2 4.0045 6.4658 3.6903 14.7097
MFH-ino GDSC1 4.326 6.172 1.7344 0.9615
HT-1080 GDSC1; CTRP2 4.3869 6.4441 4.1125 12.0232
GCT GDSC1; CTRP2 4.5544 6.2355 4.3624 10.6061
BT-12 CTRP2 4.5704 6.88 4.1498 11.3604
Hs 729.T CTRP2 4.6394 8.9689 3.2931 14.5834
RD GDSC1; CTRP2 4.8778 7.2241 4.3297 9.8293
RKN GDSC1; CTRP2 4.8992 6.3604 4.696 8.3578
SK-UT-1 GDSC1; CTRP2 5.5289 7.9372 4.6403 6.9784
Rh30 GDSC1 5.7758 7.2149 1.9004 0.0441
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 2.9977 5.8156 2.779 21.0562
H-STS CTRP2 3.762 8.5087 2.6216 19.4606
P-STS CTRP2 6.019 9.144 4.4733 6.6528
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 8.9662 21.4159 0.6367 16.1122
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MPP 89 GDSC1; CTRP2 2.1791 5.4369 1.975 26.449
IST-Mes1 GDSC1; CTRP2 2.6396 5.308 2.5007 23.1587
MSTO-211H GDSC1; CTRP2 2.9742 4.9263 2.9198 20.6378
NCI-H28 GDSC1; CTRP2 3.2917 6.5077 2.9021 19.7206
NCI-H2452 GDSC1; CTRP2 3.4182 4.9766 2.3761 2.7646
ACC-MESO-1 CTRP2 4.213 6.5873 3.8749 13.415
JL-1 CTRP2 4.5638 9.171 3.1239 15.4462
NCI-H2052 GDSC1; CTRP2 4.5821 7.0864 4.0794 11.5996
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
22Rv1 GDSC1; CTRP2 2.3464 4.5798 1.2362 6.266
PC-3 GDSC1 3.3035 5.9687 1.2653 5.7067
VCaP GDSC1; CTRP2 3.4751 5.8013 3.303 17.7135
LNCaP clone FGC GDSC1; CTRP2 3.5996 8.4346 2.4864 20.4111
DU145 GDSC1; CTRP2 4.4577 7.8815 3.6104 13.7703
PaCa-3 CTRP2 5.283 7.2029 4.7518 7.107
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 4.5369 6.9421 4.0897 15.9271
A-253 GDSC1; CTRP2 5.2883 7.4276 4.6532 7.4916
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 1.5515 3.2827 1.1241 13.0862
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-620 CTRP2 -4.6125 -2.6496 -4.6125 70.9522
SNU-5 GDSC1; CTRP2 -3.4721 4.5049 -3.965 69.9907
KATO III CTRP2 -0.8475 3.6452 -0.9835 46.1207
Hs 746.T GDSC1; CTRP2 -0.2381 7.6011 -1.2923 43.6503
IM95 GDSC1; CTRP2 1.1315 7.3442 0.2789 35.2612
RERF-GC-1B GDSC1 1.6663 4.3076 0.7593 15.3026
SNU-16 GDSC1; CTRP2 1.9384 3.0101 1.9382 27.3554
NUGC-4 GDSC1; CTRP2 1.9827 4.3495 1.0334 8.3859
HGC-27 GDSC1; CTRP2 2.1845 2.8432 2.1845 25.7149
RF-48 GDSC1 2.2453 4.9176 0.9819 11.223
SNU-1 GDSC1; CTRP2 2.5625 5.8366 2.2992 24.1081
SNU-216 CTRP2 2.6955 4.5343 2.6654 22.4121
Fu97 GDSC1; CTRP2 2.79 7.3949 2.0502 24.3108
GCIY GDSC1 3.0476 5.6542 1.2418 6.5681
AGS GDSC1; CTRP2 3.1079 4.5818 1.7899 1.6722
TGBC11TKB GDSC1 3.2411 5.1376 1.6154 3.3071
ECC10 GDSC1; CTRP2 3.3448 5.5424 3.2186 18.4187
GSS CTRP2 3.4779 4.7227 3.4658 17.1387
MKN28 GDSC1 3.5519 5.9101 1.4491 3.8052
TMK-1 GDSC1 3.5721 5.8812 1.4742 3.5895
HuG1-N CTRP2 3.7782 9.1939 2.3329 20.5149
23132/87 GDSC1; CTRP2 3.8285 6.3354 3.5408 15.7813
SCH GDSC1 3.88 5.1052 1.9518 0.4392
GSU CTRP2 4.1088 5.2828 4.081 12.9891
OCUM-1 GDSC1 4.1821 6.2782 1.627 1.6402
LMSU CTRP2 4.2017 14.5057 0.1946 26.5625
MKN74 CTRP2 4.359 9.7558 2.6479 17.8293
MKN45 GDSC1; CTRP2 4.5015 17.3338 -0.9325 28.7506
SNU-719 CTRP2 4.5213 6.3892 1.4576 0.4195
KE-39 CTRP2 4.546 7.3286 3.9408 12.2368
HSC-39 GDSC1 4.6032 6.3803 1.7708 0.6096
ECC12 CTRP2 4.6511 6.1559 4.4919 9.8433
SNU-601 CTRP2 4.6993 7.2242 4.1447 11.0294
NUGC-3 GDSC1; CTRP2 5.0311 7.1025 4.5405 8.5954
MKN7 GDSC1; CTRP2 5.1191 8.1121 4.1655 9.8856
NCI-N87 GDSC1; CTRP2 5.2851 8.97 3.9089 13.5374
SH-10-TC CTRP2 5.4266 7.6243 4.6948 6.9899
MKN1 GDSC1; CTRP2 5.7561 9.2004 4.2202 8.2421
SNU-668 CTRP2 6.3018 9.2403 4.6556 7.3038
SNU-1077 CTRP2 3.718 5.4885 3.6328 15.7902
SNG-M GDSC1; CTRP2 4.7165 7.2868 4.1358 11.0183
SNU-685 CTRP2 4.7222 8.0562 3.7996 12.3409
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 -1.4484 5.7504 -2.0543 49.933
CGTH-W-1 GDSC1; CTRP2 0.4024 6.2481 -0.1697 39.0791
HTC-C3 GDSC1 2.1543 4.0192 1.3509 8.6892
8505C GDSC1; CTRP2 2.5853 4.2686 1.5835 3.7536
K5 GDSC1 2.8234 5.0673 1.3675 6.2562
WRO GDSC1 3.1054 5.0259 1.5821 3.8644
ML-1 [Human leukemia] GDSC1; CTRP2 3.1583 6.6785 1.3274 8.802
8305C GDSC1; CTRP2 3.1652 4.9817 3.1159 19.3481
B-CPAP GDSC1; CTRP2 3.502 5.5958 3.3782 17.3636
TT2609-C02 GDSC1; CTRP2 3.7907 5.9748 3.6036 15.6671
KMH-2 GDSC1 4.1044 5.8677 1.7557 1.0758
ASH-3 GDSC1 4.6199 5.9948 1.9141 0.2072
FTC-238 CTRP2 4.6498 6.2573 4.4594 9.9665
CAL-62 GDSC1; CTRP2 4.7312 6.3758 4.5088 9.5443
IHH-4 GDSC1 4.7813 6.1022 1.9342 0.1318
FTC-133 GDSC1; CTRP2 5.7065 7.464 5.0365 4.9371
TT GDSC1; CTRP2 5.8728 12.4438 -0.1458 6.9189
BHT-101 GDSC1; CTRP2 6.1695 9.7367 4.3014 9.0934
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BICR 18 CTRP2 0.7869 5.5802 0.4265 36.1107
YD-10B CTRP2 1.9002 4.5294 1.8275 37.9397
BB30-HNC GDSC1 1.9384 4.0732 1.1287 11.3021
SCC-15 GDSC1 1.9999 4.8325 0.8098 13.5071
PCI-06A GDSC1 2.0515 5.3428 0.6019 14.8702
PCI-38 GDSC1 2.0812 3.8871 1.351 8.9821
SAS GDSC1 2.0864 3.9722 1.3136 9.2524
SCC-25 GDSC1; CTRP2 2.1261 5.099 1.9843 26.5864
JHU-011 GDSC1 2.3738 4.0565 1.5206 6.5252
OSC-20 GDSC1 2.3944 4.9762 1.0778 9.9283
NCI-H3118 GDSC1 2.413 5.2767 0.943 10.9071
KOSC-2 GDSC1 2.4752 5.7184 0.7732 11.9842
SAT [Human HNSCC] GDSC1 2.5469 4.6596 1.3592 7.1958
OSC-19 GDSC1 2.5696 5.7702 0.8235 11.2714
HSC-2 GDSC1; CTRP2 2.6384 4.3014 2.6217 22.7471
LB771-HNC GDSC1 2.6552 5.3289 1.1111 8.7717
PCI-04B GDSC1 2.7947 5.9809 0.895 9.9757
HO-1-u-1 GDSC1 2.9149 4.7105 1.6058 4.1736
Ca9-22 GDSC1 2.9503 4.6615 1.6531 3.7259
YD-8 CTRP2 2.9994 4.3884 2.9892 20.3202
Detroit 562 GDSC1; CTRP2 3.0512 11.875 0.371 29.022
SNU-1076 CTRP2 3.0637 6.8683 2.5343 21.7447
SCC-9 GDSC1; CTRP2 3.1588 7.8405 2.2719 22.4358
BICR 78 GDSC1 3.1756 6.2021 1.0659 7.535
CAL-27 GDSC1; CTRP2 3.4102 5.4995 3.2979 17.9344
BICR 31 GDSC1; CTRP2 3.4642 6.4117 3.1203 18.4076
BHY GDSC1; CTRP2 3.4953 6.8356 3.0124 18.7155
CAL-33 GDSC1; CTRP2 3.5332 5.4035 3.4485 17.0193
PE/CA-PJ49 CTRP2 3.5673 5.8915 3.3812 17.1499
HO-1-N-1 GDSC1 3.7737 5.4495 1.7703 1.3809
JHU-022 GDSC1 3.7964 6.447 1.3498 3.9853
PE/CA-PJ15 GDSC1; CTRP2 3.9466 6.611 3.5785 15.2945
SKN-3 GDSC1 4.0591 6.2308 1.5865 2.0288
DOK GDSC1 4.0774 7.9362 0.8368 6.909
HSC-4 GDSC1; CTRP2 4.1684 6.7612 3.7647 13.9571
SNU-46 CTRP2 4.2335 11.9158 1.4903 29.0804
PE/CA-PJ34 (clone C12) CTRP2 4.3323 6.4647 4.0464 12.4284
PCI-30 GDSC1 4.3526 6.1461 1.7557 0.8478
PCI-15A GDSC1 4.3579 6.482 1.627 1.4345
SNU-1066 CTRP2 4.4599 8.4377 3.3624 14.7506
KON GDSC1 4.5633 6.4121 1.7429 0.7369
BICR 6 CTRP2 4.674 8.2016 3.6848 12.9222
BB49-HNC GDSC1 4.7617 6.45 1.807 0.4106
BICR 22 GDSC1; CTRP2 4.9927 8.9976 3.6203 12.4132
SNU-1214 CTRP2 5.0055 7.9083 4.1499 13.9335
BICR 10 GDSC1 5.0136 6.5678 1.8576 0.2041
PE/CA-PJ41 (clone D2) CTRP2 5.1858 8.7717 3.9125 10.7667
SNU-1041 CTRP2 5.2622 10.2501 3.2587 13.2831
FaDu GDSC1; CTRP2 5.6979 8.996 4.2708 8.1514
BICR 16 CTRP2 5.7993 7.9499 4.8804 5.3872
BICR 56 CTRP2 5.8597 10.5534 3.6342 10.4792
SNU-899 CTRP2 6.0633 9.0187 4.573 8.3787
SCC-4 GDSC1; CTRP2 6.1389 7.674 5.307 2.9221
HSC-3 GDSC1; CTRP2 7.4229 11.6998 4.2667 5.1903
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RT-4 GDSC1; CTRP2 1.6976 5.697 1.3907 29.9897
UM-UC-1 CTRP2 2.0271 4.2126 1.9927 26.8794
RT-112 GDSC1 2.2105 4.1494 1.3354 8.5919
SW780 GDSC1 2.535 4.1686 1.5944 5.3904
JMSU-1 CTRP2 2.6506 5.1478 2.5413 22.9822
253J CTRP2 2.7 4.0008 2.6958 22.2948
TCCSUP GDSC1; CTRP2 3.0196 4.6403 1.7083 2.2234
5637 GDSC1; CTRP2 3.2679 4.8859 1.746 1.656
KMBC-2 CTRP2 3.3338 22.001 -4.2919 37.027
J82 GDSC1; CTRP2 4.0769 6.3961 3.7918 14.1215
U-BLC1 CTRP2 4.2187 6.7876 3.809 13.6465
BC-3C CTRP2 4.2626 6.418 3.9864 12.8554
SCaBER CTRP2 4.3303 6.9055 3.8841 13.0466
BFTC-905 GDSC1; CTRP2 4.3325 6.1436 4.1481 12.0533
VM-CUB-1 CTRP2 4.426 7.5696 3.7136 13.4464
HT-1197 GDSC1; CTRP2 4.431 6.7747 4.0415 12.1638
T24 GDSC1; CTRP2 4.5136 7.0922 4.0048 12.0755
CAL-29 GDSC1; CTRP2 4.5187 6.4957 4.2374 11.1744
647V GDSC1; CTRP2 4.7444 6.9104 4.322 10.2176
HT-1376 GDSC1; CTRP2 4.9136 7.3144 4.3271 9.7461
UM-UC-3 GDSC1; CTRP2 5.6888 9.4976 4.0132 9.2474
253J-BV CTRP2 5.6977 9.4531 4.0432 9.1036
SW1710 GDSC1; CTRP2 6.6967 9.3316 4.9076 3.6565
639V GDSC1; CTRP2 6.7192 9.3589 4.9103 3.6115
KU-19-19 GDSC1; CTRP2 7.8717 10.6442 5.0296 1.7744
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KGN GDSC1 1.0096 4.5696 -0.0056 23.8237
SW954 GDSC1 1.0731 4.1457 0.2519 21.7703
PA-1 GDSC1 1.6099 2.6124 1.4598 10.3432
BPH-1 GDSC1 1.6371 4.5075 0.635 16.3615
NEC8 GDSC1 2.0735 2.7438 1.8956 4.8047
OV17R GDSC1 2.169 4.0087 1.3691 8.4888
ME-180 GDSC1 2.1794 5.7273 0.5211 14.9676
CAL-39 GDSC1 2.2051 4.0257 1.3924 8.1654
C-33 A GDSC1 2.2952 4.4757 1.2451 8.9812
ACC-OV7 GDSC1 2.378 7.043 0.0308 17.66
NT2-D1 GDSC1 2.4105 5.0938 1.0324 10.2238
Ca Ski GDSC1 2.4183 5.3305 0.9204 11.0624
SW962 GDSC1 2.4675 4.8375 1.207 8.66
UWB1.289 GDSC1 2.4705 6.0978 0.5798 13.45
OVCA420 GDSC1 2.5067 5.9997 0.6582 12.7379
OVMIU GDSC1 2.739 5.1353 1.2713 7.2587
HEY GDSC1 2.847 4.5914 1.6164 4.2775
OMC-1 [Human cervical carcinoma] GDSC1 2.9669 6.8672 0.5872 11.7169
C-4-I GDSC1 3.0178 4.9628 1.5544 4.2895
OVCA433 GDSC1 3.0593 6.5741 0.8006 9.8575
DSH1 GDSC1 3.0693 5.0099 1.5662 4.0709
PEO1 GDSC1 3.2428 8.0161 0.2268 13.3921
HT-3 GDSC1 3.3699 5.5756 1.4923 3.8965
DoTc2 4510 GDSC1 3.3725 7.459 0.5941 10.4376
SiSo GDSC1 3.6071 5.6901 1.5801 2.8061
JAR GDSC1 3.6119 5.3805 1.7178 1.9189
LB831-BLC GDSC1 3.7495 5.7801 1.6185 2.31
SW756 GDSC1 3.8001 5.5311 1.7495 1.461
HeLa GDSC1; CTRP2 4.2332 5.5359 4.1798 12.2483
HEC-1 GDSC1 4.2895 5.9675 1.797 0.7304
MS751 GDSC1 4.2909 6.2015 1.7076 1.1153
JEG-3 GDSC1 4.3261 6.0287 1.7891 0.7337
SiHa GDSC1 4.432 5.7567 1.9287 0.237
NCC-IT GDSC1 4.4532 6.0674 1.8261 0.5141
JHOS-3 GDSC1 4.5326 10.0759 0.1244 10.5498
SKG-IIIa GDSC1 4.6798 6.7898 1.6487 1.0226
SKN GDSC1 4.7979 6.6057 1.7649 0.5158
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cabozantinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Cabozantinib and Lenvatinib. Thyroid cancer [2D10] [9]
Coadministration of a Drug Treating the Disease Different from Cabozantinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Cabozantinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [10]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Cabozantinib and Ivosidenib. Acute myeloid leukaemia [2A60] [11]
Arn-509 DMT81LZ Major Increased metabolism of Cabozantinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Cabozantinib and Oliceridine. Acute pain [MG31] [12]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Ivabradine. Angina pectoris [BA40] [9]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Cabozantinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [13]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Levalbuterol. Asthma [CA23] [14]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Cabozantinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [10]
Talazoparib DM1KS78 Moderate Decreased clearance of Cabozantinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [15]
Tucatinib DMBESUA Major Decreased metabolism of Cabozantinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [16]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Cabozantinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [9]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Cabozantinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [17]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [14]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Cabozantinib and Levomilnacipran. Chronic pain [MG30] [18]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Cabozantinib and Regorafenib. Colorectal cancer [2B91] [9]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Cabozantinib and Osilodrostat. Cushing syndrome [5A70] [9]
Lumacaftor DMCLWDJ Major Increased metabolism of Cabozantinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [10]
MK-8228 DMOB58Q Moderate Decreased metabolism of Cabozantinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [19]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Cabozantinib and Vortioxetine. Depression [6A70-6A7Z] [18]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Cabozantinib and Ingrezza. Dystonic disorder [8A02] [9]
Stiripentol DMMSDOY Moderate Decreased metabolism of Cabozantinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Cabozantinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Tazemetostat DMWP1BH Moderate Increased metabolism of Cabozantinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [10]
Ripretinib DM958QB Moderate Decreased clearance of Cabozantinib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [16]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Cabozantinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [9]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Cabozantinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [9]
Cobicistat DM6L4H2 Major Decreased metabolism of Cabozantinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Aliskiren DM1BV7W Moderate Decreased clearance of Cabozantinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [20]
Lesinurad DMUR64T Moderate Increased metabolism of Cabozantinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [10]
Berotralstat DMWA2DZ Major Decreased clearance of Cabozantinib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [21]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [9]
Naloxegol DML0B41 Minor Decreased clearance of Cabozantinib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [22]
Brigatinib DM7W94S Moderate Increased metabolism of Cabozantinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [10]
Ceritinib DMB920Z Major Decreased metabolism of Cabozantinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cabozantinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [10]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Cabozantinib and Osimertinib. Lung cancer [2C25] [23]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Cabozantinib and Selpercatinib. Lung cancer [2C25] [9]
GDC-0199 DMH0QKA Major Decreased clearance of Cabozantinib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [16]
IPI-145 DMWA24P Moderate Decreased metabolism of Cabozantinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [19]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Cabozantinib and Acalabrutinib. Mature B-cell lymphoma [2A85] [24]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Cabozantinib and Ibrutinib. Mature B-cell lymphoma [2A85] [19]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Cabozantinib and Ponatinib. Mature B-cell lymphoma [2A85] [25]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Cabozantinib and Arry-162. Melanoma [2C30] [19]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Cabozantinib and Vemurafenib. Melanoma [2C30] [20]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Cabozantinib and LGX818. Melanoma [2C30] [9]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Cabozantinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [9]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Siponimod. Multiple sclerosis [8A40] [16]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Cabozantinib and Ozanimod. Multiple sclerosis [8A40] [26]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Cabozantinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Cabozantinib and Ruxolitinib. Myeloproliferative neoplasm [2A20] [19]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Cabozantinib and Vorapaxar. Myocardial infarction [BA41-BA43] [19]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Cabozantinib and Entrectinib. Non-small cell lung cancer [2C25] [9]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Cabozantinib and Rucaparib. Ovarian cancer [2C73] [9]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Cabozantinib and MK-4827. Ovarian cancer [2C73] [9]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Cabozantinib and Triclabendazole. Parasitic worm infestation [1F90] [9]
Abametapir DM2RX0I Moderate Decreased metabolism of Cabozantinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [27]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Cabozantinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [28]
Enzalutamide DMGL19D Major Increased metabolism of Cabozantinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [10]
Relugolix DMK7IWL Major Decreased clearance of Cabozantinib due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [29]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Cabozantinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [19]
Larotrectinib DM26CQR Moderate Decreased metabolism of Cabozantinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Cabozantinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Cabozantinib and Pitolisant. Somnolence [MG42] [9]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Cabozantinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [30]
Elagolix DMB2C0E Moderate Increased metabolism of Cabozantinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [10]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Cabozantinib and Betrixaban. Venous thromboembolism [BD72] [19]
⏷ Show the Full List of 66 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Ammonium hydroxide E00687 Not Available Alkalizing agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cabozantinib 20 mg capsule 20 mg Oral Capsule Oral
Cabozantinib S-Malate eq 80mg base capsule eq 80mg base Capsule Oral
Cabozantinib S-Malate eq 20mg base capsule eq 20mg base Capsule Oral
Cabozantinib S-Malate eq 20mg base tablet eq 20mg base Tablet Oral
Cabozantinib S-Malate eq 40mg base tablet eq 40mg base Tablet Oral
Cabozantinib S-Malate eq 60mg base tablet eq 60mg base Tablet Oral
Cabozantinib 20 mg tablet 20 mg Oral Tablet Oral
Cabozantinib 40 mg tablet 40 mg Oral Tablet Oral
Cabozantinib 60 mg tablet 60 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Cabozantinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Clinical pipeline report, company report or official report of Exelixis (2011).
5 Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
6 FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
7 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
8 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
11 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
12 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
13 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
14 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
15 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
18 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
19 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
20 Canadian Pharmacists Association.
21 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
22 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
23 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
25 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
26 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
27 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
28 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
29 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
30 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.